

CITATION REPORT

List of articles citing

Gene expression profiling predicts clinical outcome of breast cancer

DOI: 10.1038/415530a
Nature, 2002, 415, 530-6.

Source: <https://exaly.com/paper-pdf/34729237/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2209	.		
2208	p-Medicine: From data sharing and integration via VPH models to personalized medicine. 2011 , 5, 218		12
2207	Integrated gene expression analysis of multiple microarray data sets based on a normalization technique and on adaptive connectionist model.		1
2206	Adrenocortical function in epilepsy: II. The role of corticosterone in the mechanism and management of epilepsy. 1961 , 11, 246-246		2
2205	The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme. 1975 , 14, 5294-9		686
2204	Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. 1994 , 20, 987		1
2203	Gene expression profiling can distinguish tumor subclasses of breast carcinomas. 2001 , 132-161		1
2202	Technique of microarrays: microarray platforms. 2001 , 8-26		
2201	Prediction of response and resistance to treatment by gene expression profiling. 2001 , 212-237		
2200	Hypertension, angiotensin II, and oxidative stress. 2002 , 346, 1999-2001		180
2199	Gene expression studies using microarrays: principles, problems, and prospects. 2002 , 26, 256-70		114
2198	SELDI ProteinChip array in oncoproteomic research. 2002 , 1, 273-80		68
2197	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. 2002 , 16, 681-6		119
2196	Progress in the treatment of breast cancer in the elderly. 2002 , 13 Suppl 4, 207-10		9
2195	Pre-validation and inference in microarrays. 2002 , 1, Article1		81
2194	Yellow pages to the transcriptome. 2002 , 3, 791-807		24
2193	A common reference for cDNA microarray hybridizations. 2002 , 30, e116		57

2192	Analyzing array data using supervised methods. 2002 , 3, 403-15	59
2191	Phenomenology and scientific progress. 2002 , 1, 436-7	36
2190	Information management systems for pharmacogenomics. 2002 , 3, 651-67	6
2189	Classification and prediction in pharmacogenetics--context, construction and validation. 2002 , 3, 157-60	0
2188	Radiotherapy for breast cancer. 2002 , 346, 862-4	4
2187	Molecular signatures of breast cancer--predicting the future. 2002 , 347, 2067-8	22
2186	Molecular characteristics of diffuse large-B-cell lymphoma. 2002 , 346, 1998-9	8
2185	[Function and responsibility of an interdisciplinary tumor center. Need for a "cancer center" for multimodal therapy concepts]. 2002 , 127, 901-6	
2184	Application of toxicogenomics to drug development. 2002 , 2, 337-45	11
2183	Chapter 23. Tumor classification for tailored cancer therapy. 2002 , 37, 225-236	
2182	Practical approaches to analyzing results of microarray experiments. 2002 , 27, 125-32	76
2181	Gene expression analysis using cDNA microarrays. 2002 , Chapter 4, Unit 4.28	3
2180	Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. 2002 , 9, 339-44	8
2179	Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. 2002 , 8, 461-8	75
2178	DNA microarrays: a bridge between genome sequence information and biological understanding. 2002 , 10, 389-408	3
2177	Sample Preparation and Supplementary Tools. 97-161	
2176	An Introduction to DNA Microarrays. 2002 , 9-21	4
2175	Loss of BRCA1Gene Expression in Breast Carcinoma. 2002 , 361-369	

2174	Gene expression profiles of mouse submandibular gland development: FGFR1 regulates branching morphogenesis in vitro through BMP- and FGF-dependent mechanisms. 2002 , 129, 5767-78	160
2173	Gene expression signatures may predict clinical outcome. 2002 , 4, 1	
2172	Perspective: prostate cancer susceptibility genes. 2002 , 143, 2029-40	37
2171	The pathology of inherited breast cancer. 2002 , 34, 309-14	45
2170	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. 2002 , 161, 1223-33	133
2169	Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging?. 2002 , 161, 1973-7	2
2168	Editorial radiotherapy and oncology 2002: predictive assays for normal tissue damage. 2002 , 64, 125-9	39
2167	Time-resolved fluorescence imaging in biology and medicine. 2002 , 35, R61-R76	164
2166	Microarrays in pharmacogenomics--advances and future promise. 2002 , 3, 589-601	37
2165	A gene-expression signature as a predictor of survival in breast cancer. 2002 , 347, 1999-2009	5020
2164	Algorithms in Bioinformatics. 2002 ,	3
2163	Expression profiling predicts outcome in breast cancer. 2003 , 5, 57-8	123
2162	Expression profiling to predict outcome in breast cancer: the influence of sample selection. 2003 , 5, 23-6	32
2161	Mutations in DNA damage response genes and breast cancer susceptibility. 2002 , 4, 1	2
2160	Defining the galaxy of gene expression in breast cancer. 2002 , 4, 141-4	13
2159	Microarrays and molecular markers for tumor classification. 2002 , 3, comment2005	12
2158	Baclofen: possible therapy for gastro-oesophageal reflux?. 2002 , &NA;, 17	
2157	Biomedical imaging in the postgenomic era: opportunities and challenges. 2002 , 9, 999-1003	7

2156	Perspective: microarray technology, seeing more than spots. 2002 , 143, 1983-9	43
2155	Toxicogenomics: an opportunity to optimise drug development and safety evaluation. 2002 , 1, 275-86	28
2154	Gene-expression profiling and identification of patients at high risk of breast cancer. 2002 , 360, 173-4; author reply 174	11
2153	BRCA1: mechanisms of inactivation and implications for management of patients. 2002 , 360, 1007-14	99
2152	Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. 2002 , 296, 497-506	12
2151	Identification of genes induced by BRCA1 in breast cancer cells. 2002 , 299, 839-46	188
2150	Impact of the Human Genome Project on the clinical management of sporadic cancers. 2002 , 3, 349-56	11
2149	Applications of microarrays in the pharmaceutical industry. 2002 , 2, 551-4	18
2148	The promise of biomarkers in cancer screening and detection. 2002 , 8, 288-93	82
2147	Gene Expression Patterns in Breast Cancer May Identify Specific Tumor Phenotypes and Predict Disease Outcome. 2002 , 3, 240-242	
2146	Functional genomics and the breast cancer problem. 2002 , 1, 15-7	17
2145	Gene expression correlates of clinical prostate cancer behavior. 2002 , 1, 203-9	1829
2144	Focus on breast cancer. 2002 , 1, 319-22	76
2143	Recent developments in DNA microarrays. 2002 , 5, 334-7	68
2142	Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. 2002 , 38, 1730-8	15
2141	Dietary protein quantity and quality affect rat hepatic gene expression. 2002 , 132, 3632-7	71
2140	Endostatin: are the 2 years up yet?. 2002 , 20, 3758-60	13
2139	Status of lymph node staging. 2002 , 91, 263-7	3

2138	HER-2/Neu signaling and therapeutic approaches in breast cancer. 2002 , 15, 13-24	7
2137	The Future of Cancer Research. 2002 , 17, 38-40	
2136	Breast cancer 2002: where do we stand?. 2002 , 52, 253-5	3
2135	Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. 2002 , 3, 31	105
2134	Molecular markers in the diagnosis and staging of breast cancer. 2002 , 12, 305-18	5
2133	Percutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery. 2002 , 11, 501-8	2
2132	Genotype-phenotype mapping: genes as computer programs. 2002 , 18, 555-9	57
2131	Turning quantity into quality: novel quality assurance strategies for data produced by high-throughput genomics technologies. 2002 , 1, 139-146	2
2130	Computational selection of distinct class- and subclass-specific gene expression signatures. 2002 , 35, 160-70	45
2129	Altered methylation patterns in cancer cell genomes: cause or consequence?. 2002 , 1, 299-305	243
2128	Optimal gene expression analysis by microarrays. 2002 , 2, 353-61	128
2127	Applications of antisense and siRNAs during preclinical drug development. 2002 , 7, 912-7	40
2126	mRNA differential display of gene expression in colonic carcinoma. 2002 , 23, 1667-76	23
2125	Highlight: BRCA1 and BRCA2 proteins in breast cancer. 2002 , 59, 68-83	11
2124	Current Awareness on Comparative and Functional Genomics. 2002 , 3, 293-304	2
2123	Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. 2002 , 102, 86-90	28
2122	Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. 2002 , 95, 2465-72	22
2121	Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. 2002 , 9, 941-3	72

2120	A study of estrogen signaling using DNA microarray in human breast cancer. 2002 , 9, 308-11	15
2119	Genetische Risikofaktoren des Mammakarzinoms. 2002 , 35, 527-536	4
2118	Molekulare Frauenheilkunde. 2002 , 35, 872-880	2
2117	Mammakarzinom - prognostische und prädiktive Faktoren. 2002 , 8, 808-816	2
2116	Symposium 1: Everything you want to know about molecular pathology. 2002 , 41, 1-11	2
2115	Symposium 15: Expression and profiling in surgical pathology. 2002 , 41, 249-262	0
2114	Fuzzy neural network applied to gene expression profiling for predicting the prognosis of diffuse large B-cell lymphoma. 2002 , 93, 1207-12	40
2113	DNA methylation analysis: a powerful new tool for lung cancer diagnosis. 2002 , 21, 5450-61	243
2112	Control of the centriole and centrosome cycles by ubiquitination enzymes. 2002 , 21, 6209-21	17
2111	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. 2002 , 21, 7034-41	34
2110	Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice. 2002 , 21, 6559-66	15
2109	Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. 2002 , 21, 7593-7	68
2108	The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. 2002 , 21, 8994-9007	99
2107	Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. 2002 , 82, 1525-33	194
2106	The molecular outlook. <i>Nature</i> , 2002 , 415, 484-5	50.4 76
2105	On the offensive. <i>Nature</i> , 2002 , 416, 470-4	50.4 14
2104	Picture this. <i>Nature</i> , 2002 , 418, 11-3	50.4 15
2103	E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). 2002 , 4, 358-66	274

2102	Medical applications of microarray technologies: a regulatory science perspective. 2002 , 32 Suppl, 474-9	191
2101	Options available--from start to finish--for obtaining data from DNA microarrays II. 2002 , 32 Suppl, 481-9	221
2100	From patterns to pathways: gene expression data analysis comes of age. 2002 , 32 Suppl, 502-8	444
2099	Molecular portraits and the family tree of cancer. 2002 , 32 Suppl, 533-40	223
2098	Dancing the two-step. 2002 , 2, 156-156	
2097	Tailor-made therapy. 2002 , 2, 157-157	
2096	Epithelial-mesenchymal transitions in tumour progression. 2002 , 2, 442-54	5249
2095	The fundamental role of epigenetic events in cancer. 2002 , 3, 415-28	4311
2094	Design issues for cDNA microarray experiments. 2002 , 3, 579-88	583
2093	Prognosis of breast cancer and gene expression profiling using DNA arrays. 2002 , 975, 217-31	31
2092	RNA expression profiling as prognostic tool in renal patients: toward nephrogenomics. 2002 , 62, 1125-35	27
2091	Gene expression profiling: methodological challenges, results, and prospects for addiction research. 2002 , 121, 241-56	41
2090	Economics and quality of care for patients with acute coronary syndromes: the impending crisis. 2002 , 25, 19-15	
2089	[New aspects of molecular biology diagnosis. Array technology and expression profile for characterization of rheumatic diseases]. 2002 , 61, 396-404	1
2088	Associations between gene expressions in breast cancer and patient survival. 2002 , 111, 411-20	72
2087	Validated genomic approach to study differentially expressed genes in complex tissues. 2002 , 27, 1027-33	34
2086	Expression profiling with oligonucleotide arrays: technologies and applications for neurobiology. 2002 , 27, 1005-26	8
2085	Application of DNA microarrays in pharmacogenomics and toxicogenomics. 2002 , 19, 1773-8	45

2084	Can metabolomics be used for assessing nutritive-dependent human diseases?. 2002 , 1, 223-230	2
2083	NF-kappaB and breast cancer. 2002 , 26, 282-309	57
2082	Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. 2003 , 14, 329-50	21
2081	p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. 2003 , 82, 1-9	14
2080	Expression profiling of human breast cancers and gene regulation by progesterone receptors. 2003 , 8, 257-68	44
2079	Interrogating mouse mammary cancer models: insights from gene expression profiling. 2003 , 8, 321-34	10
2078	Laser capture microdissection and advanced molecular analysis of human breast cancer. 2003 , 8, 335-45	37
2077	Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. 2003 , 37, 198-207	228
2076	General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. 2003 , 88, S4-7; discussion S11-3	16
2075	Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. 2003 , 5, 489-97	12
2074	Pharmacogenomic applications in clinical drug development. 2003 , 52 Suppl 1, S57-60	5
2073	Genexpressionsmuster als Prognoseindikator bei Brustkrebs. 2003 , 36, 1011-1015	1
2072	Differential gene expression in the periprosthetic membrane: lubricin as a new possible pathogenetic factor in prosthesis loosening. 2003 , 443, 57-66	22
2071	Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. 2003 , 443, 508-17	93
2070	DNA microarrays in clinical practice: past, present, and future. 2003 , 3, 1-3	16
2069	Profiling cancer. 2003 , 15, 213-20	12
2068	New data on chemotherapy in the adjuvant setting. 2003 , 12, 373-8	12
2067	Histopathology of primary breast cancer 2003. 2003 , 12, 391-6	8

2066	Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness. 2003 , 12, 529-37	7
2065	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. 2003 , 3, 173-83	353
2064	FANCF methylation contributes to chemoselectivity in ovarian cancer. 2003 , 3, 417-20	64
2063	A multigenic program mediating breast cancer metastasis to bone. 2003 , 3, 537-49	2050
2062	Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. 2003 , 4, 209-21	852
2061	Biomarker Discovery by Tissue Microdissection and ProteinChip [®] Array Analysis. 2003 , 27, 79-84	1
2060	Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. 2003 , 8, 134-41	106
2059	Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. 2003 , 8, 356-63	40
2058	The use of gene-specific IgY antibodies for drug target discovery. 2003 , 8, 364-71	73
2057	Tumor markers: discovery to practice. 2003 , 8, 441-3	1
2056	Cancer pharmacogenomics: current and future applications. 2003 , 1603, 99-111	37
2055	Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues. 2003 , 27, 405-11	14
2054	Epidemiology, cancer genetics and microarrays: making correct inferences, using appropriate designs. 2003 , 19, 690-5	40
2053	Neural network analysis of lymphoma microarray data: prognosis and diagnosis near-perfect. 2003 , 4, 13	54
2052	Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. 2003 , 3, 3	73
2051	Distinct subtypes of serous ovarian carcinoma identified by p53 determination. 2003 , 91, 504-12	60
2050	Are cancers dependent on oncogenes or on aneuploidy?. 2003 , 143, 89-91	33
2049	Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. 2003 , 147, 28-35	38

2048	The relevance of alternative RNA splicing to pharmacogenomics. 2003 , 21, 346-53	71
2047	Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. 2003 , 38, 207-14	16
2046	Review of proteomics with applications to genetic epidemiology. 2003 , 24, 83-98	51
2045	Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. 2003 , 97, 2960-71	157
2044	Insights into the mechanisms of lymph node metastasis. 2003 , 98, 413-23	321
2043	Author reply. 2003 , 98, 1326-1327	4
2042	Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. 2003 , 98, 1325-6; author reply 1326-7	7
2041	The biology of breast carcinoma. 2003 , 98, 1327-8; author 1328-9	1
2040	Author reply. 2003 , 98, 1328-1329	7
2039	Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. 2003 , 98, 1569-77	92
2038	Breast cancer revisited using DNA array-based gene expression profiling. 2003 , 103, 565-71	46
2037	Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. 2003 , 105, 53-60	84
2036	Prognostic significance of reduced expression of beta-N-acetylgalactosaminylated N-linked oligosaccharides in human breast cancer. 2003 , 105, 533-41	23
2035	Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. 2003 , 106, 74-7	17
2034	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. 2003 , 107, 854-62	16
2033	BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. 2003 , 89, 120-32	7
2032	BRCA1 gene in breast cancer. 2003 , 196, 19-41	191
2031	Validation of consensus between proteomic and clinical chemistry datasets by applying a new randomisation F-test for generalised procrustes analysis. 2003 , 490, 365-378	5

2030	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. 2003 , 27, 95-120	125
2029	Simultaneous classification and relevant feature identification in high-dimensional spaces: application to molecular profiling data. 2003 , 83, 729-743	50
2028	Cancer classification using gene expression data. 2003 , 28, 243-268	160
2027	Interdisciplinary sciences in the 21st century. 2003 , 14, 328-31	7
2026	Current and potential uses for DNA microarrays in transplantation medicine: lessons from other disciplines. 2003 , 62, 93-103	2
2025	Aspects of cancer immunotherapy. 2003 , 81, 79-85	8
2024	Beyond Herceptin and Gleevec. 2003 , 7, 490-5	81
2023	Oligodeoxyribonucleotide probe accessibility on a three-dimensional DNA microarray surface and the effect of hybridization time on the accuracy of expression ratios. 2003 , 3, 6	47
2022	Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. 2003 , 43, 118-26	113
2021	Stem cells in normal breast development and breast cancer. 2003 , 36 Suppl 1, 59-72	444
2020	Signal Transduction and Communication in Cancer Cells 117th Advanced Course of the International School of Medical Science. 2003 , 3, NA-NA	
2019	Application of differential display, with in situ hybridization verification, to microscopic samples of breast cancer tissue. 2003 , 84, 207-12	5
2018	Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. 2003 , 88, 1091-4	73
2017	Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. 2003 , 89, 314-9	36
2016	Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. 2003 , 88, 1831-8	17
2015	Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. 2003 , 89, 1031-4	43
2014	Genetics of gene expression surveyed in maize, mouse and man. <i>Nature</i> , 2003 , 422, 297-302	50.4 1244
2013	Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. 2003 , 4, 336-42	10

2012	Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. 2003 , 22, 2192-205	277
2011	Genomic profiling of gastric cancer predicts lymph node status and survival. 2003 , 22, 1872-9	95
2010	Effects of methylation on expression of TMS1/ASC in human breast cancer cells. 2003 , 22, 3475-88	53
2009	Gene-expression profiling in human cutaneous melanoma. 2003 , 22, 3076-80	97
2008	Chronic myelogenous leukemia molecular signature. 2003 , 22, 3952-63	101
2007	BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. 2003 , 22, 5572-8	65
2006	Biologic and therapeutic role of HER2 in cancer. 2003 , 22, 6570-8	304
2005	Advantages and limitations of microarray technology in human cancer. 2003 , 22, 6497-507	204
2004	Expression profiling of epithelial plasticity in tumor progression. 2003 , 22, 7155-69	249
2003	Molecular analysis of transitional cell carcinoma using cDNA microarray. 2003 , 22, 7702-10	42
2002	Survivin, versatile modulation of cell division and apoptosis in cancer. 2003 , 22, 8581-9	756
2001	DNA arrays in clinical oncology: promises and challenges. 2003 , 83, 305-16	32
2000	Genetic background is an important determinant of metastatic potential. 2003 , 34, 23-4; author reply 25	88
1999	A molecular signature of metastasis in primary solid tumors. 2003 , 33, 49-54	1973
1998	Identifying distinct classes of bladder carcinoma using microarrays. 2003 , 33, 90-6	401
1997	Proteomics: the first decade and beyond. 2003 , 33 Suppl, 311-23	558
1996	Gene expression phenotypic models that predict the activity of oncogenic pathways. 2003 , 34, 226-30	210
1995	Chromosome aberrations in solid tumors. 2003 , 34, 369-76	603

1994	Predicting the future of breast cancer. 2003 , 9, 16-8	18
1993	Myelin management. 2003 , 9, 18-18	
1992	Road map to metastasis. 2003 , 9, 999-1000	83
1991	Prediction power. 2003 , 3, 82-82	
1990	Ovarian cancer: strategies for overcoming resistance to chemotherapy. 2003 , 3, 502-16	883
1989	Cancer pharmacogenetics: polymorphisms, pathways and beyond. 2003 , 3, 912-20	160
1988	Issues and progress with protein kinase inhibitors for cancer treatment. 2003 , 2, 296-313	410
1987	Is proteomics heading in the wrong direction?. 2003 , 4, 74-80	107
1986	Application of microarray technology in environmental and comparative physiology. 2003 , 65, 231-59	141
1985	[Sentinel lymph node versus functional genomics for prognosis and treatment of breast cancer]. 2003 , 120, 414-6	
1984	Microarray analysis in the clinical management of cancer. 2003 , 17, 377-87	14
1983	Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. 2003 , 78, 307-17	20
1982	Use of Metabolomics to Discover Metabolic Patterns Associated with Human Diseases. 2003 , 199-215	3
1981	Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. 2003 , 3, 635-47	32
1980	Toxicogenomics: challenges and opportunities. 2003 , 140-141, 145-8	28
1979	From peas to "chips" - the new millennium of molecular biology: a primer for the surgeon. 2003 , 1, 21	3
1978	Spectral biclustering of microarray data: coclustering genes and conditions. 2003 , 13, 703-16	401
1977	High-throughput analysis of total RNA expression profiles by capillary gel electrophoresis. 2003 , 75, 4415-22	12

1976	Tissue microarray study for classification of breast tumors. 2003 , 73, 3189-99	31
1975	Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. 2003 , 163, 543-52	76
1974	Multicolor deconvolution microscopy of thick biological specimens. 2003 , 162, 373-9	12
1973	The molecular detection of micrometastatic breast cancer. 2003 , 186, 351-8	20
1972	From the messenger RNA saga to the transcriptome era. 2003 , 326, 893-900	5
1971	Gene expression profiling of breast carcinomas using nylon DNA arrays. 2003 , 326, 1031-9	3
1970	Molecular diagnostics: an FDA perspective. 2003 , 3, 129-40	10
1969	Diagnosing male factor infertility using microarrays. 2003 , 24, 783-9	32
1968	Targeted therapy in non-small cell lung cancer: myth or reality. 2003 , 41 Suppl 1, S3-8	29
1967	Prognostic factors in ovarian cancer: current evidence and future prospects. 2003 , 1, 127-145	14
1966	Gene expression monitoring accurately predicts medulloblastoma positive and negative clinical outcomes. 2003 , 533, 110-4	8
1965	Component plane presentation integrated self-organizing map for microarray data analysis. 2003 , 538, 117-24	47
1964	Integration and cross-validation of high-throughput gene expression data: comparing heterogeneous data sets. 2003 , 546, 98-102	26
1963	Schizosaccharomyces pombe Int6 and Ras homologs regulate cell division and mitotic fidelity via the proteasome. 2003 , 112, 207-17	74
1962	MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. 2003 , 113, 207-19	426
1961	Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?. 2003 , 113, 821-3	139
1960	A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. 2003 , 114, 323-34	353
1959	Gene expression predictors of breast cancer outcomes. 2003 , 361, 1590-6	509

1958	DNA microarrays in breast cancer: the promise of personalised medicine. 2003 , 361, 1576-7	47
1957	New biology of the oestrogen receptor. 2003 , 362, 260-2	12
1956	Child survival: a global health challenge. 2003 , 362, 262	33
1955	Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. 2003 , 362, 362-9	708
1954	The ErbB receptors and their role in cancer progression. 2003 , 284, 99-110	516
1953	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. 2003 , 69, 121-5	71
1952	Epigenetic gene silencing in cancer initiation and progression. 2003 , 190, 125-33	141
1951	Differentially expressed genes in gastric tumors identified by cDNA array. 2003 , 190, 199-211	22
1950	Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. 2003 , 200, 97-105	36
1949	Repeated observation of breast tumor subtypes in independent gene expression data sets. 2003 , 100, 8418-23	4262
1948	Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. 2003 , 95, 1482-5	737
1947	Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. 2003 , 95, 14-8	837
1946	Classification of cancers by expression profiling. 2003 , 13, 97-103	50
1945	Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. 2003 , 39, 932-44	145
1944	Global functional profiling of gene expression. 2003 , 81, 98-104	479
1943	Cancer diagnosis and microarrays. 2003 , 35, 119-24	30
1942	Study of suboptimum treatment response: lessons from breast cancer. 2003 , 4, 177-85	49
1941	Classifying human cancer by analysis of gene expression. 2003 , 9, 5-10	21

1940	Estrogen and growth factor signaling pathway: basic approaches for clinical application. 2003 , 86, 433-42	12
1939	Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 2003 , 86, 301-7	38
1938	Nucleic acid microarrays: an overview. 2003 , 9, 155-158	6
1937	Bioinformatics: Organisms from Venus, Technology from Jupiter, Algorithms from Mars. 2003 , 9, 237-278	8
1936	The ErbB receptors and their role in cancer progression. 2003 , 103-114	1
1935	Microarrays bring new insights into understanding of breast cancer metastasis to bone. 2004 , 6, 61-4	31
1934	The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. 2003 , 5, 320-8	18
1933	Microarray technology and its effect on breast cancer (re)classification and prediction of outcome. 2003 , 5, 303-4	13
1932	American Society for Clinical Oncology 39th Annual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: breast cancer neoadjuvant and adjuvant chemotherapy--prognostic and predictive markers. 2003 , 5, 289-93	1
1931	The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. 2003 , 5, 154-9	32
1930	Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. 2003 , 5, 101-6	169
1929	Multiclass classification of microarray data with repeated measurements: application to cancer. 2003 , 4, R83	90
1928	Clustering gene-expression data with repeated measurements. 2003 , 4, R34	132
1927	Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. 2003 , 4, R21	50
1926	Gene profiling for defining targets for new therapeutics in autoimmune diseases. 2003 , 5, 47-50	4
1925	Looking beyond morphology: cancer gene expression profiling using DNA microarrays. 2003 , 21, 937-49	38
1924	From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. 2003 , 100, 7737-42	517
1923	Identification of a gene expression signature associated with pediatric AML prognosis. 2003 , 102, 1849-56	151

1922	Breast and ovarian cancer. 2003 , 348, 2339-47	446
1921	Molecular Diagnosis of Infectious Diseases. 2003 ,	1
1920	PATHOGENESIS OF RESPIRATORY DISEASES: NEW SOLUTIONS TO OLD PROBLEMS?. 2003 , 29, 3-92	
1919	Proteomic prediction of disease outcome in cancer : clinical framework and current status. 2003 , 3, 107-15	6
1918	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. 2003 , 100, 10393-8	1562
1917	Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. 2003 , 144, 4562-74	806
1916	Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. 2003 , 2, 443-52	69
1915	Clinical application of cDNA microarrays in oncology. 2003 , 8, 252-8	64
1914	Using gene expression ratios to predict outcome among patients with mesothelioma. 2003 , 95, 598-605	151
1913	Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. 2003 , 21, 740-53	51
1912	Gene expression profiles of primary breast tumors maintained in distant metastases. 2003 , 100, 15901-5	367
1911	New approaches to cancer therapy. 2003 , 14, 813-6	5
1910	Ligand-independent activation of estrogen receptor alpha by XBP-1. 2003 , 31, 5266-74	102
1909	In situ-synthesized novel microarray optimized for mouse stem cell and early developmental expression profiling. 2003 , 13, 1011-21	91
1908	Variation in gene expression patterns in human gastric cancers. 2003 , 14, 3208-15	253
1907	Microarray technologies 2003 -- an overview. 2003 , 4, 251-6	17
1906	Molecular diagnostics by microelectronic microchips. 2003 , 41, 462-7	13
1905	Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. 2003 , 12, 3245-58	39

1904	Gene-expression signatures in breast cancer. 2003 , 348, 1715-7; author reply 1715-7	16
1903	A neural survival factor is a candidate oncogene in breast cancer. 2003 , 100, 10931-6	100
1902	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. 2003 , 100, 11606-11	1295
1901	Biomarker Discovery by Tissue Microdissection and ProteinChip® Array Analysis/Identifizierung von Biomarkern Bei Gewebemikrodissektion und ProteinChip® Array Analyse. 2003 , 27, 79-84	
1900	Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. 2003 , 12 Spec No 2, R153-7	103
1899	Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations. 2003 , 2, 201-209	122
1898	Microarray data analysis and mining. 2004 , 94, 67-90	7
1897	Gene Selection and Sample Classification Using a Genetic Algorithm and k-Nearest Neighbor Method. 2003 , 216-229	4
1896	Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. 2003 , 89, 1599-604	131
1895	Applications of array technology: identification of molecular targets in bladder cancer. 2003 , 89, 2172-7	46
1894	A Bayesian missing value estimation method for gene expression profile data. 2003 , 19, 2088-96	471
1893	Molecular classification of familial non-BRCA1/BRCA2 breast cancer. 2003 , 100, 2532-7	157
1892	Prostate cancer susceptibility genes: lessons learned and challenges posed. 2003 , 10, 225-59	71
1891	Anthracyclines: is more, better and/or more dangerous?. 2003 , 14, 663-5	4
1890	Extending the utility of gene profiling data by bridging microarray platforms. 2003 , 100, 10585-7	12
1889	DNA arrays: applications and implications for circadian biology. 2003 , 18, 96-105	29
1888	Gene expression profiles of human breast cancer progression. 2003 , 100, 5974-9	722
1887	Irruption of genomics in the search for disease related genes. 2003 , 52 Suppl 2, ii1-5	1

1886	Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. 2003 , 31, 3775-81	280
1885	The systemic progression of human cancer: a focus on the individual disseminated cancer cell--the unit of selection. 2003 , 89, 35-67	48
1884	Idiopathic Pulmonary Fibrosis. Proceedings of the 1st Annual Pittsburgh International Lung Conference. October 2002. 2003 , 29, S1-105	28
1883	MODEL-BASED CLUSTERING IN GENE EXPRESSION MICROARRAYS: AN APPLICATION TO BREAST CANCER DATA. 2003 , 13, 579-592	13
1882	Gene expression patterns in ovarian carcinomas. 2003 , 14, 4376-86	273
1881	Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. 2003 , 49, 752-60	208
1880	In Reply:. 2003 , 21, 3180-3180	
1879	Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. 2003 , 13, 2291-305	317
1878	Specificity of short interfering RNA determined through gene expression signatures. 2003 , 100, 6347-52	426
1877	Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy: July 1416, 2002, The Gant Conference Center, Aspen, Colorado. 2003 , 31, 140-170	1
1876	Handbook of Proteomic Methods. 2003 ,	
1875	Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. 2003 , 21, 3469-78	387
1874	Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. 2003 , 13, 1719-27	87
1873	Microarray standard data set and figures of merit for comparing data processing methods and experiment designs. 2003 , 19, 956-65	76
1872	Multivariate curve resolution for hyperspectral image analysis: applications to microarray technology. 2003 , 4959, 55	16
1871	HIN-1 and the nosology of breast cancer. 2003 , 2, 564-5	1
1870	INT6: A Link Between the Proteasome and Tumorigenesis. 2003 , 2, 80-82	11
1869	Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: Diffuse down-regulation is associated with immune evasion and brain metastasis. 2003 , 23, 965	2

1868	Gene expression phenotypes of Arabidopsis associated with sensitivity to low temperatures. 2003 , 132, 893-906	120
1867	SEP: score for expression profile-a novel method for predicting clinical outcome in breast cancer.	1
1866	[Gene expression analysis using DNA microarrays in soft tissue and bone tumors]. 2003 , 128, 2030-6	
1865	The insulin-like growth factors and insulin-signalling systems: an appealing target for breast cancer therapy?. 2003 , 35, 857-71	23
1864	Pharmacogenomics: implications and considerations for pharmacists. 2003 , 4, 321-30	16
1863	Genomic & proteomic technological advances in cancer research. 2003 , 4, 245-9	6
1862	Noninvasive molecular detection of cancer -- the bench and the bedside. 2003 , 10, 691-706	17
1861	Differential expression, class discovery and class prediction using S-PLUS and S+ArrayAnalyzer. 2003 , 5, 38-47	2
1860	The Emergence of Pharmacogenomics. 2003 , 33, 133-137	2
1859	Nuclear factor-kappa B as a predictor of treatment response in breast cancer. 2003 , 15, 405-11	25
1858	Physiopathology of liver metastasis. 2003 , 103, 444-7	1
1857	Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. 2003 , 129, 760-70	43
1856	Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities. 2003 , 9, 442-53	18
1855	. 2003 , 237, 474-482	16
1854	Molecular classification of breast carcinomas using tissue microarrays. 2003 , 12, 27-34	142
1853	CHIPing soft tissue tumors: will the paradigms be changed?. 2003 , 10, 1-7	4
1852	Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. 2003 , 27, 199-205	96
1851	DNA expression analysis: serial analysis of gene expression, microarrays and kidney disease. 2003 , 12, 407-14	12

1850	Gene-expression profiles and breast-cancer prognosis. 2003 , 10, 338-46	1
1849	Estimation of population effects in synchronized budding yeast experiments. 2003 ,	3
1848	Global Functional Profiling of Gene Expression Data. 2003 , 306-325	4
1847	Molecular mechanisms of bone metastasis and therapeutic implications. 2003 , S100-4	30
1846	Rating the risk factors for breast cancer. 2003 , 237, 474-82	155
1845	Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. 2003 , 75, 1323-30	83
1844	Current World Literature. 2003 , 12, 463-482	
1843	Supervised analysis when the number of candidate features (p) greatly exceeds the number of cases (n). 2003 , 5, 31-36	52
1842	Identification of endothelial cell genes by combined database mining and microarray analysis. 2003 , 13, 249-62	99
1841	HER-2/neu testing in breast cancer. 2003 , 120 Suppl, S53-71	19
1840	Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. 2003 , 101, 4998-5006	109
1839	Supervised classification for gene network reconstruction. 2003 , 31, 1497-502	15
1838	Demystified...tissue microarray technology. 2003 , 56, 198-204	93
1837	Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers. 2003 , 18, 241-272	16
1836	Molecular Characterization of Breast Cancer Aggressiveness. 2003 , 18, 36-39	
1835	Genetic Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. 2003 , 18, 54-56	2
1834	The clinical geneticist and the "new genetics". 2003 , 178, 458-62	14
1833	Informatics United. 2003 , 42, 126-133	10

1832	Using DNA microarrays for diagnostic and prognostic prediction. 2003 , 3, 587-95	31
1831	Poster Sessions. 2003 , 25, 249-307	78
1830	Quantitative Real-Time RT-PCR Analysis of Eight Novel Estrogen-Regulated Genes in Breast Cancer. 2003 , 18, 123-129	13
1829	BRCA1 and estrogen signaling in breast cancer. 2003 , 18, 11-20	4
1828	Microarray of recombinant antibodies using a streptavidin sensor surface self-assembled onto a gold layer. 2003 , 34, 124-30	37
1827	Optimizing stringency for expression microarrays. 2003 , 35, 828-35	13
1826	Microarray-Based Cancer Diagnosis with Artificial Neural Networks. 2003 , 34, S30-S35	28
1825	Open Source Software for the Analysis of Microarray Data. 2003 , 34, S45-S51	172
1824	Gene Expression Databases and Data Mining. 2003 , 34, S36-S44	14
1823	Application of DNA array analyses in the management of gastrointestinal cancer patients. 2003 , 21, 309-14	4
1822	Clinical relevance of prognostic factors in axillary node-negative breast cancer. 2003 , 26, 438-45	7
1821	Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. 2004 , 19, 275-82	22
1820	Combining nearest neighbor classifiers versus cross-validation selection. 2004 , 3, Article12	9
1819	Universal mouse reference RNA derived from neonatal mice. 2004 , 37, 464-8	11
1818	Large-scale transcriptional profiling of murine mammary development. 2004 , 19, 47-57	2
1817	Rational surveillance programs for early stage breast cancer patients after primary treatment. 2004 , 21, 47-54	9
1816	Invasive growth: a genetic program. 2004 , 48, 451-6	31
1815	Curated databases and their role in clinical bioinformatics. 2004 , 13, 121-136	

1814	Genomic approaches to identifying breast cancer susceptibility factors. 2004 , 19, 3-9	5
1813	. 2004 ,	4
1812	. 2004 ,	107
1811	Novel technologies and recent advances in metastasis research. 2004 , 48, 573-81	27
1810	. 2004 ,	46
1809	. 2004 ,	7
1808	Bibliography. 2004 , 251-258	
1807	Expression profiling and breast cancer biology. 2004 , 19, 29-34	1
1806	Genomic approaches to understanding and treating breast cancer. 2004 , 19, 35-46	4
1805	Seeing the unseen: Microarray-based gene expression profiling in vision. 2004 , 45, 2457-62	6
1804	Gene Microarray Technologies for Cancer Drug Discovery and Development. 2004 , 141-186	
1803	Pathobiology of Human Cerebrovascular Malformations: Basic Mechanisms and Clinical Relevance. 2004 ,	54
1802	Gene expression profiling in breast cancer research. 2004 , 19, 23-7	1
1801	Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. 2004 , 89, 994-1005	68
1800	Analysis of DNA microarray data. 2004 , 4, 1357-70	22
1799	Microarray analysis of human nervous system gene expression in neurological disease. 2004 , 60, 135-51	1
1798	Adjustment of systematic microarray data biases. 2004 , 20, 105-14	313
1797	Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. 2004 , 5, 709-19	99

1796	Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. 2004 , 4, 403-24	19
1795	Hematopoietic Growth Factors in Oncology. 2004 ,	
1794	Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. 2004 , 170, 911-9	131
1793	Classification of cDNA array genes that have a highly significant discriminative power due to their unique distribution in four brain regions. 2004 , 23, 661-74	4
1792	Principles of Molecular Oncology. 2004 ,	6
1791	A Bayesian network classification methodology for gene expression data. 2004 , 11, 581-615	39
1790	Signature of a silent killer: expression profiling in epithelial ovarian cancer. 2004 , 4, 157-67	25
1789	Extreme value distribution based gene selection criteria for discriminant microarray data analysis using logistic regression. 2004 , 11, 215-26	18
1788	Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. 2004 , 18, 402-11	113
1787	Treating brain metastases: current approaches and future directions. 2004 , 4, 1015-22	5
1786	Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. 2004 , 101, 9309-14	790
1785	Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. 2004 , 3, 624-31	12
1784	siRNA-mediated gene silencing: a global genome view. 2004 , 32, 3836-45	53
1783	CleanEx: a database of heterogeneous gene expression data based on a consistent gene nomenclature. 2004 , 32, D542-7	29
1782	Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. 2004 , 10, 6418-31	53
1781	Decoding randomly ordered DNA arrays. 2004 , 14, 870-7	241
1780	Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). 2004 , 22, 961-2	14
1779	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. 2004 , 10, 6143-51	175

1778	Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. 2004 , 64, 3525-32	103
1777	Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. 2004 , 64, 5068-73	124
1776	Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. 2004 , 32, e74	152
1775	Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. 2004 , 43, 947-51	66
1774	Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. 2004 , 96, 1208-19	109
1773	DNA amplification method tolerant to sample degradation. 2004 , 14, 2357-66	73
1772	Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. 2004 , 10, 155-65	73
1771	Trawling for genes that predict response to breast cancer adjuvant therapy. 2004 , 22, 2267-9	13
1770	Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. 2004 , 64, 844-56	190
1769	Microarrays as a tool to investigate the biology of aging: a retrospective and a look to the future. 2004 , 2004, re7	24
1768	The 'subsequent artificial neural network' (SANN) approach might bring more classificatory power to ANN-based DNA microarray analyses. 2004 , 20, 3544-52	40
1767	Session 1: Metastasis. 2004 , 32, 730-731	
1766	Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. 2004 , 64, 3807-13	284
1765	Reliability of gene expression ratios for cDNA microarrays in multiconditional experiments with a reference design. 2004 , 32, e29	28
1764	RESPONSE: Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. 2004 , 96, 714-714	1
1763	Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. 2004 , 64, 3037-45	208
1762	Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. 2004 , 64, 6883-91	165
1761	A gene expression signature associated with metastatic outcome in human leiomyosarcomas. 2004 , 64, 7201-4	65

1760	Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. 2004 , 22, 2284-93	439
1759	RRE: a tool for the extraction of non-coding regions surrounding annotated genes from genomic datasets. 2004 , 20, 2848-50	12
1758	Intracellular patterns of Her-2/neu, ras, and ploidy abnormalities in primary human breast cancers predict postoperative clinical disease-free survival. 2004 , 10, 3042-52	11
1757	A molecular signature of the Nottingham prognostic index in breast cancer. 2004 , 64, 2962-8	55
1756	Genomics and proteomics tools for compound mode-of-action studies in drug discovery. 2004 , 5, 395-404	11
1755	An integrative genomics approach to the reconstruction of gene networks in segregating populations. 2004 , 105, 363-74	178
1754	Universal RNA reference materials for gene expression. 2004 , 50, 1464-71	67
1753	Cell-type-specific responses to chemotherapeutics in breast cancer. 2004 , 64, 4218-26	307
1752	Profiling the evolution of human metastatic bladder cancer. 2004 , 64, 7813-21	82
1751	Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. 2004 , 10, 2272-83	58
1750	The prognostic value of BCAR1 in patients with primary breast cancer. 2004 , 10, 6194-202	47
1749	Identification and validation of cell surface antigens for antibody targeting in oncology. 2004 , 11, 659-87	91
1748	Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation. 2004 , 57, 1278-87	4
1747	BRCA1 functions as a breast stem cell regulator. 2004 , 41, 1-5	122
1746	Curcumin Derivatives: Potential for Prostate Cancer Management: ADDANKI P. KUMAR, GRETCHEN E. GARCIA, RITA GHOSH, RAJENDRAN V. RAJNARAYANAN, ¹ WILLIAM L. ALWORTH, ¹ AND THOMAS J. SLAGA, Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Cancer Center, Denver, Colorado 80202, ¹ Department of Chemistry, University of Colorado, Boulder, Colorado 80509	
1745	Gene Expression Profiling of Node-Negative Breast Tumors Reveals Metastatic Recurrence Risk: ANAND IMMANENI, ANNA TSIMELZON, SUSAN G. HILSENBECK, CRAIG ALLRED, PETER O'CONNELL, AND WILLIAM R. BRINKLEY, Breast Center, Department of Molecular and Cellular Biology, Department of Pathology at the Baylor College of Medicine, Houston, Texas 77030. 2004 , 32, 163-163	
1744	Intensity-based analysis of two-colour microarrays enables efficient and flexible hybridization designs. 2004 , 32, e41	31
1743	Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. 2004 , 101, 8431-6	174

1742	Signal transducer and activator of transcription-5 activation and breast cancer prognosis. 2004 , 22, 2053-60	185
1741	Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. 2004 , 50, 826-35	61
1740	Effects of hemolysis on the Roche ammonia method for Hitachi analyzers. 2004 , 50, 976-7	19
1739	Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. 2004 , 64, 7279-87	28
1738	A statistical method for identifying differential gene-gene co-expression patterns. 2004 , 20, 3146-55	121
1737	MYC is amplified in BRCA1-associated breast cancers. 2004 , 10, 499-507	71
1736	Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. 2004 , 101, 18147-52	90
1735	Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. 2004 , 64, 8585-94	365
1734	[Neoadjuvant therapy of breast cancer]. 2004 , 44, 92-101	4
1733	The Microrevolution: Applications and impacts of microarray technology on molecular biology and medicine (Review). 2004 , 13, 483	1
1732	Tissue microarrays - big potential from small samples (Review). 2004 , 25, 167	
1731	A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. 2004 , 25, 397	1
1730	Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip [®] technology. 2004 , 24, 885	2
1729	Basal and luminal breast cancers: Basic or luminous? (Review). 2004 , 25, 249	4
1728	Finding the bEST routes to cancer. 2004 , 3, 1090-1	7
1727	Survivin' cancer. 2004 , 3, 180-3	6
1726	Aneuploidy Approaching a Perfect Score in Predicting and Preventing Cancer: Highlights from a Conference Held in Oakland, CA in January, 2004. 2004 , 3, 821-826	20
1725	Metastasizing and non-metastasizing tumors likely evolve from DNA phenotypes via independent pathways. 2004 , 3, 1250-1	3

1724	Hard Wired Genotype in Metastatic Breast Cancer. 2004 , 3, 754-755	14
1723	Using microarrays to predict resistance to chemotherapy in cancer patients. 2004 , 5, 611-25	13
1722	How to understand a complex reality: statistical issues in microarray experiments. Interview by Nadine Lemmens. 2004 , 5, 9-13	
1721	A technical triade for proteomic identification and characterization of cancer biomarkers. 2004 , 64, 4099-104	91
1720	New challenges in gene expression data analysis and the extended GEPAS. 2004 , 32, W485-91	44
1719	Genetic epidemiology of BRCA1. 2004 , 3, 509-14	19
1718	Gene Expression Signatures, Cancer Cell Evolution and Metastatic Progression. 2004 , 3, 28-30	20
1717	Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. 2004 , 64, 8558-65	155
1716	Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay. 2004 , 3, 453-7	37
1715	Systematic benchmarking of microarray data classification: assessing the role of non-linearity and dimensionality reduction. 2004 , 20, 3185-95	190
1714	Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. 2004 , 10, 958-63	36
1713	Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells. 2004 , 24, 3682-91	66
1712	Using protein expressions to predict survival in clear cell renal carcinoma. 2004 , 10, 5464-71	188
1711	Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. 2004 , 24, 3992-4003	260
1710	Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. 2004 , 22, 1630-7	117
1709	Requirement for Arf6 in breast cancer invasive activities. 2004 , 101, 6647-52	213
1708	Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. 2004 , 10, 5546-53	61
1707	Membrane-associated and secreted genes in breast cancer. 2004 , 64, 8682-7	17

1706	Microarrays in veterinary diagnostics. 2004 , 5, 249-55	9
1705	Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. 2004 , 50, 975-6	22
1704	Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. 2004 , 64, 1522-33	279
1703	Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. 2004 , 10, 2776-83	40
1702	A novel, high-performance random array platform for quantitative gene expression profiling. 2004 , 14, 2347-56	150
1701	Coexpression analysis of human genes across many microarray data sets. 2004 , 14, 1085-94	571
1700	Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. 2004 , 101, 11428-31	41
1699	Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. 2004 , 90, 1531-7	56
1698	New chondrocyte genes discovered by representational difference analysis of chondroinduced human fibroblasts. 2004 , 176, 41-53	21
1697	Differential gene-expression profiles associated with gastric adenoma. 2004 , 90, 216-23	23
1696	Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. 2004 , 90, 1414-21	139
1695	Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. 2004 , 90, 173-81	37
1694	A prognostic index for operable, node-negative breast cancer. 2004 , 90, 1933-41	16
1693	DNA microarray time series analysis: automated statistical assessment of circadian rhythms in gene expression patterning. 2004 , 383, 149-66	97
1692	DNA Repair in Cancer Therapy. 2004 ,	1
1691	Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. 2004 , 32, e137	73
1690	p53-Mediated Oxidative Stress and Apoptosis: S. PERWEZ HUSSAIN, PAUL AMSTAD, PEIJUN HE, ANA ROBLES, SHAWN LUPOLD, SAGAR SENGUPTA, MASATO ICHIMIYA, SHU OKAMURA, MATHEW MOAKE, KATHLEEN FORRESTER, AND CURTIS C. HARRIS, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892. 2004 , 32, 163-164	
1689	A versatile assay for high-throughput gene expression profiling on universal array matrices. 2004 , 14, 878-85	151

1688	Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. 2004 , 2, E7	698
1687	Genomics and proteomics: expression arrays in clinical oncology. 2004 , 15 Suppl 4, iv163-5	4
1686	Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. 2004 , 96, 712-4; author reply 714	28
1685	DJ*vu for breast cancer two?. 2004 , 96, 497-9	3
1684	Gene expression analysis on biochemical networks using the Potts spin model. 2004 , 20, 1500-5	12
1683	Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus. 2004 , 25, 2293-301	23
1682	Modeling metastasis in vivo. 2005 , 26, 513-23	330
1681	Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. 2004 , 96, 712-3; author reply 714	63
1680	Impact of microarray technology in clinical oncology. 2004 , 22, 312-20	23
1679	Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. 2004 , 10, 3457-64	99
1678	Molecular medicine: a clinician's primer on microarrays. 2004 , 34, 565-9	1
1677	Molecular footprints of human lung cancer progression. 2004 , 95, 197-204	114
1676	Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. 2004 , 95, 218-25	181
1675	Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. 2004 , 95, 496-502	68
1674	Applications of microarrays to histopathology. 2004 , 44, 97-108	73
1673	Analysing the platelet transcriptome. 2004 , 87 Suppl 2, 42-6	13
1672	Histological quantitation of tumour angiogenesis. 2004 , 112, 413-30	123
1671	Gene expression signatures in chronic and aggressive periodontitis: a pilot study. 2004 , 112, 216-23	31

1670	Developing a classifier for the Habitats Directive grassland types in Denmark using species lists for prediction. 2004 , 7, 71-80	30
1669	DNA microarray technology and its applications in dermatology. 2004 , 13, 593-606	37
1668	Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion. 2004 , 85, 373-9	33
1667	The analysis of placement values for evaluating discriminatory measures. 2004 , 60, 528-35	69
1666	Rules of evidence for cancer molecular-marker discovery and validation. 2004 , 4, 309-14	415
1665	Dissecting the metastatic cascade. 2004 , 4, 448-56	1026
1664	BRCA1 and BRCA2: 1994 and beyond. 2004 , 4, 665-76	694
1663	Hallmarks of 'BRCAness' in sporadic cancers. 2004 , 4, 814-9	1268
1662	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. 2004 , 23, 1377-91	265
1661	Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. 2004 , 23, 2484-98	220
1660	Identification and validation of an ERBB2 gene expression signature in breast cancers. 2004 , 23, 2564-75	101
1659	Ubiquitin and breast cancer. 2004 , 23, 2079-88	98
1658	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. 2004 , 23, 6316-24	29
1657	Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. 2004 , 23, 6684-92	132
1656	Mutation of GATA3 in human breast tumors. 2004 , 23, 7669-78	209
1655	Prediction of high risk Ewing's sarcoma by gene expression profiling. 2004 , 23, 8997-9006	84
1654	Host genetics and tumour metastasis. 2004 , 90, 752-5	76
1653	Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. 2004 , 90, 1422-8	30

1652	Molecular profiling of breast cancer: clinical implications. 2004 , 90, 1120-4	77
1651	Balancing false positives and false negatives for the detection of differential expression in malignancies. 2004 , 91, 1160-5	12
1650	Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. 2004 , 91, 1813-20	44
1649	A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. 2004 , 84, 191-202	9
1648	Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. 2004 , 17, 756-64	28
1647	Novel endothelial cell markers in hepatocellular carcinoma. 2004 , 17, 1198-210	69
1646	Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. <i>Nature</i> , 2004 , 430, 797-802	50.4 457
1645	Earth science: putting the squeeze on oxidation. <i>Nature</i> , 2004 , 428, 379	50.4 1
1644	Medicine: profile of a tumour. <i>Nature</i> , 2004 , 428, 379-82	50.4 19
1643	Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. 2004 , 4, 193-207	178
1642	Pharmacogenetics in the treatment of breast cancer. 2004 , 4, 143-53	48
1641	DNA microarrays and data analysis: an overview. 2004 , 136, 500-3	13
1640	Genomic approaches in cancer biology. 2004 , 136, 511-8	3
1639	Application of microarray profiling to clinical trials in cancer. 2004 , 136, 519-23	13
1638	Prognostic predictor with multiple fuzzy neural models using expression profiles from DNA microarray for metastases of breast cancer. 2004 , 98, 193-9	22
1637	Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. 2004 , 5, 365-74	316
1636	Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. 2004 , 5, 489-500	516
1635	[Colorectal cancer: prognostic molecular markers]. 2004 , 28, 21-32	5

1634	Apoptosis in cancer--implications for therapy. 2004 , 31, 90-119	120
1633	Therapeutic targeting in the estrogen receptor hormonal pathway. 2004 , 31, 28-38	81
1632	Improving patient care through molecular diagnostics. 2004 , 31, 14-20	21
1631	Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. 2004 , 135, 121-4	17
1630	Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. 2004 , 93, 292-300	13
1629	A combinational feature selection and ensemble neural network method for classification of gene expression data. 2004 , 5, 136	77
1628	Combining gene expression data from different generations of oligonucleotide arrays. 2004 , 5, 159	42
1627	Comparing functional annotation analyses with Catmap. 2004 , 5, 193	67
1626	Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments. 2004 , 5, 29	66
1625	A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. 2004 , 5, 47	43
1624	Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling. 2004 , 5, 9	40
1623	Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. 2004 , 5, 94	87
1622	Preoperative chemotherapy and endocrine therapy in patients with breast cancer. 2004 , 5, 198-207	5
1621	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. 2004 , 5, 348-52	81
1620	Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. 2004 , 5, 364-9	12
1619	A primer on gene expression and microarrays for machine learning researchers. 2004 , 37, 293-303	24
1618	Mapping high-dimensional data onto a relative distance plane--an exact method for visualizing and characterizing high-dimensional patterns. 2004 , 37, 366-79	28
1617	Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. 2004 , 68, 1171-85	97

1616	Radioresistance in carcinoma of the breast. 2004 , 13, 452-60	85
1615	Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. 2004 , 153, 127-32	18
1614	Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. 2004 , 154, 63-6	47
1613	Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines. 2004 , 155, 57-62	29
1612	A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. 2004 , 5, 607-16	774
1611	Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. 2004 , 5, 597-605	218
1610	Molecular characterization of the tumor microenvironment in breast cancer. 2004 , 6, 17-32	1038
1609	Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. 2004 , 56, 65-81	115
1608	TMS1/ASC: the cancer connection. 2004 , 9, 5-18	72
1607	BAX Inhibitor-1, an ancient cell death suppressor in animals and plants with prokaryotic relatives. 2004 , 9, 299-307	144
1606	Relevance of breast cancer cell lines as models for breast tumours: an update. 2004 , 83, 249-89	602
1605	Gene expression profiling: from microarrays to medicine. 2004 , 24, 213-24	38
1604	Breast cancer biomarkers and molecular medicine: part II. 2004 , 4, 169-88	35
1603	Diagnostic classification of cancer using DNA microarrays and artificial intelligence. 2004 , 1020, 49-66	28
1602	Data-driven computer simulation of human cancer cell. 2004 , 1020, 132-53	76
1601	Gene expression profiling of human cancers. 2004 , 1028, 28-37	44
1600	Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. 2004 , 130, 497-513	160
1599	Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers. 2004 , 130, 537-45	14

1598	Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. 2004 , 19, 401-13	21
1597	Das Chip-Zeitalter: gegenwärtiger Stand der Technik und Einsatzmöglichkeiten der Chip-Technologie in der Onkologie. 2004 , 10, 7-19	
1596	Les banques de tissus tumoraux appliquées au cancer du sein : pourquoi? Comment?. 2004 , 6, 93-98	1
1595	Traitement adjuvant du cancer du sein, aujourd'hui et demain: « Carte » ou « Menu »?. 2004 , 6, 99-106	
1594	Een introductie in de genetica van complexe ziekten. 2004 , 72, 53-58	1
1593	Gene expression profiling in breast cancer: from molecular portraits to personalized medicine. 2004 , 6, 192-202	1
1592	DNA microarrays--techniques and applications in microbial systems. 2004 , 49, 635-64	16
1591	Current progress in the prediction of chemosensitivity for breast cancer. 2004 , 11, 42-8	12
1590	Where next with preoperative radiation therapy for rectal cancer?. 2004 , 58, 597-602	33
1589	In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression. 2004 , 35, 595-601	9
1588	Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. 2004 , 87 Suppl 1, S3-10	28
1587	The scientific value of preoperative studies and how they can be used. 2004 , 87 Suppl 1, S19-26	26
1586	Designing the future shape of breast cancer diagnosis, prognosis and treatment. 2004 , 87 Suppl 1, S27-9	4
1585	[Microarrays]. 2004 , 43, 653-8	4
1584	Biomolecular features of clinical relevance in breast cancer. 2004 , 31 Suppl 1, S3-14	8
1583	Analysis of gastric cancer with cDNA microarray. 2004 , 54 Suppl 1, S21-4	4
1582	Role of HER2/neu in tumor progression and therapy. 2004 , 61, 2965-78	110
1581	Genchipdiagnostik. 2004 , 37, 203-209	

1580	Statistics in clinical trials. 2004 , 6, 36-41	3
1579	Inhibition of proliferation of human breast cancer MCF-7 cells by small interference RNA against LRP16 gene. 2004 , 16, 239-245	2
1578	Are tumours angiogenesis-dependent?. 2004 , 202, 5-13	103
1577	Surgical margin and Gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. 2004 , 61, 81-91	8
1576	Proteomic signature of human cancer cells. 2004 , 4, 2776-88	63
1575	Gene expression profiling for prognosis using Cox regression. 2004 , 23, 1767-80	22
1574	Proteomics: beginning to realize its promise?. 2004 , 50, 3741-4	9
1573	In situ synthesis of oligonucleotide microarrays. 2004 , 73, 579-96	178
1572	A new way to look at liver cancer. 2004 , 40, 521-3	8
1571	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. 2004 , 40, 667-76	697
1570	Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. 2004 , 39, 236-48	72
1569	Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. 2004 , 41, 65-79	42
1568	Diminished transcription of chromosome arm 4q is inversely related to local spreading of hepatocellular carcinoma. 2004 , 41, 390-4	5
1567	Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact?. 2004 , 100, 929-34	88
1566	alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. 2004 , 100, 2543-8	60
1565	Getting the right cells to the array: Gene expression microarray analysis of cell mixtures and sorted cells. 2004 , 59, 191-202	54
1564	The role of functional genomics in selecting disease targets for antibody-based therapy. 2004 , 61, 155-171	1
1563	Application of expression genomics in drug development and genomic medicine. 2004 , 62, 124-133	4

1562	Expression genomics and cancer drug development. 2004 , 62, 295-302	2
1561	Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. 2004 , 109, 703-9	24
1560	Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. 2004 , 111, 892-9	20
1559	Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. 2004 , 92, 656-63	120
1558	Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. 2004 , 200, 440-50	39
1557	Finding predictive gene groups from microarray data. 2004 , 90, 106-131	80
1556	A Bayesian approach to nonlinear probit gene selection and classification. 2004 , 341, 137-156	18
1555	State of the science: molecular classifications of breast cancer for clinical diagnostics. 2004 , 37, 572-8	13
1554	Predicting drug response based on gene expression. 2004 , 51, 205-27	14
1553	Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. 2004 , 16, 137-42	8
1552	Statistical analysis of global gene expression data: some practical considerations. 2004 , 15, 52-7	24
1551	Hypermethylation in histologically distinct classes of breast cancer. 2004 , 10, 5998-6005	102
1550	Hypermethylation of CpG islands in primary and metastatic human prostate cancer. 2004 , 64, 1975-86	416
1549	Development of a knowledge-based-multi-scheme cancer microarray data analysis system.	1
1548	A variant of SVM-RFE for gene selection in cancer classification with expression data.	10
1547	The role of cost-effectiveness analysis in the era of pharmacogenomics. 2004 , 22, 481-93	82
1546	Cross-validation for linear model with unequal variances in genomic analysis. 2004 , 14, 723-39	4
1545	Multiclass Decision Forest--a novel pattern recognition method for multiclass classification in microarray data analysis. 2004 , 23, 685-94	33

1544	Comparative study of microarray data for cancer research. 2004 , 2004, 2960-3	1
1543	Systematic analysis and nomenclature of mammalian F-box proteins. 2004 , 18, 2573-80	503
1542	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. 2004 , 10, 5367-74	2156
1541	Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. 2004 , 22, 1564-71	381
1540	Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. 2004 , 64, 4040-8	351
1539	Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. 2004 , 10, 2725-37	131
1538	Expression and motogenic activity of TFF2 in human breast cancer cells. 2004 , 25, 865-865	
1537	Using molecular markers to predict outcome. 2004 , 172, S18-21; discussion S21-2	12
1536	DNA microarray analysis of pancreatic malignancies. 2004 , 4, 587-97	36
1535	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. 2004 , 64, 830-5	307
1534	Breast Cancer Prognostic and Predictive Factors. 2004 , 7, 91-100	
1533	Predicting prostate cancer behavior using transcript profiles. 2004 , 172, S28-32; discussion S33	36
1532	Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. 2004 , 6, 611-22	156
1531	Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. 2004 , 127, 457-69	81
1530	Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. 2004 , 127, S51-5	143
1529	E15. Use of micro-array analysis to predict outcome and response in breast cancer patients. 2004 , 2, 49-50	
1528	Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. 2004 , 14, 130-46	162
1527	Microarray platforms--comparisons and contrasts. 2004 , 5, 487-502	151

1526	DNA microarrays and pharmacogenomics. 2004 , 49, 303-8	15
1525	Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. 2004 , 45 Suppl 2, S145-50	26
1524	Adjuvant therapy in elderly patients with breast cancer. 2004 , 5, 188-95; discussion 196-7	15
1523	An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. 2004 , 64, 1584-8	19
1522	Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. 2004 , 66, 429-38	72
1521	Genetic alteration and gene expression modulation during cancer progression. 2004 , 3, 9	70
1520	Methods to find out the expression of activated genes. 2004 , 2, 68	5
1519	Optimizing treatment for cervical cancer. 2004 , 3, 215-227	4
1518	Phenotype characterisation using integrated gene transcript, protein and metabolite profiling. 2004 , 3, 205-17	55
1517	caGEDA: a web application for the integrated analysis of global gene expression patterns in cancer. 2004 , 3, 49-62	71
1516	Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. 2004 , 350, 1605-16	822
1515	Creation of the whole human genome microarray. 2004 , 1, 19-28	27
1514	CNS metastases in breast cancer. 2004 , 22, 3608-17	526
1513	Thoracic manifestations of common nonpulmonary malignancies of women. 2004 , 25, 379-90	10
1512	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. 2004 , 351, 2817-26	4778
1511	A compendium to ensure computational reproducibility in high-dimensional classification tasks. 2004 , 3, Article37	61
1510	Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. 2005 , 7, R82-92	24
1509	Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?. 2004 , 6, 192-200	18

1508	A multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory results. 2004 , 6, 185-7	2
1507	Prognostic molecular markers in early breast cancer. 2004 , 6, 109-18	156
1506	Multistep tumorigenesis and the microenvironment. 2004 , 6, 93-101	74
1505	Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. 2004 , 6, R46-55	35
1504	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. 2004 , 5, R66	213
1503	Molecular tumor profiling: translating genomic insights into clinical advances. 2004 , 5, 113	2
1502	Common ground in the transcriptional profiles of wounds and tumors. 2004 , 5, 228	10
1501	Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. 2004 , 6, 140-6	12
1500	?Good Old? clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers*1. 2004 ,	
1499	Critical Review of European Experience with Neoadjuvant Therapy. 2004 , 7, 113-121	1
1498	ONCOMINE: a cancer microarray database and integrated data-mining platform. 2004 , 6, 1-6	2548
1497	Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. 2004 , 117, 927-39	2996
1496	Epithelial-mesenchymal transitions: twist in development and metastasis. 2004 , 118, 277-9	1198
1495	Genomics in the immune system. 2004 , 111, 175-85	22
1494	Prediction of hormone sensitivity by DNA microarray. 2004 , 58, 1-9	22
1493	The use of cytogenetics in understanding ovarian cancer. 2004 , 58, 17-23	16
1492	A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. 2004 , 209, 231-6	19
1491	Customizing chemotherapy for colon cancer: the potential of gene expression profiling. 2004 , 7, 209-18	14

1490	"Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. 2004 , 40, 1837-41	130
1489	Old and new markers for breast cancer prognosis: the need for integrated research on quantitative issues. 2004 , 40, 1803-6	9
1488	Genomic and proteomic technologies for individualisation and improvement of cancer treatment. 2004 , 40, 2623-32	77
1487	Biomarkers of ovarian tumours. 2004 , 40, 2604-12	68
1486	Understanding cancer at the chromosome level: 40 years of progress. 2004 , 40, 1960-7	6
1485	Gene expression microarray technologies in the development of new therapeutic agents. 2004 , 40, 2560-91	70
1484	Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. 2004 , 40, 2667-75	267
1483	Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. 2004 , 313, 931-7	28
1482	Clinico-molecular study of dedifferentiation in well-differentiated liposarcoma. 2004 , 314, 1133-40	24
1481	XBP-1 increases ERalpha transcriptional activity through regulation of large-scale chromatin unfolding. 2004 , 323, 269-74	26
1480	Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. 2004 , 325, 784-91	78
1479	Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. 2005 , 326, 218-27	59
1478	Individual-specific variation of gene expression in peripheral blood leukocytes. 2004 , 83, 980-8	119
1477	Expression and motogenic activity of TFF2 in human breast cancer cells. 2004 , 25, 865-72	22
1476	Phenotypic and microarray gene expression analysis of tri-dimensional raft-modeled human head and neck squamous cell carcinoma. 2004 , 131, 577-84	3
1475	Multi-platform, multi-site, microarray-based human tumor classification. 2004 , 164, 9-16	178
1474	Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. 2004 , 164, 23-33	83
1473	Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. 2004 , 164, 35-42	469

1472	Single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction for large numbers of gene products differentiates nondemented from neuropathological Alzheimer's disease. 2004 , 164, 795-806	4
1471	Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. 2004 , 164, 903-14	176
1470	It's the matrix! ECM, proteases, and cancer. 2004 , 164, 1141-2	23
1469	Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. 2004 , 165, 1799-807	138
1468	Biologie moléculaire des cancers. 2004 , 19, 13-22	2
1467	Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals. 2004 , 4, 1829-36	14
1466	Molecular classification of nemaline myopathies: "nontyping" specimens exhibit unique patterns of gene expression. 2004 , 15, 590-600	11
1465	Quantitative T1 mapping and absolute water content measurement using MRI. 2004 , 1265, 113-123	8
1464	Oncogenic pathways in hereditary and sporadic breast cancer. 2004 , 49, 34-43	38
1463	About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. 2004 , 219, 1-7	114
1462	Prediction of lymph node metastasis and perineural invasion of biliary tract cancer by selected features from cDNA array data. 2004 , 122, 184-94	25
1461	A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. 2004 , 41, 399-406	29
1460	Telomere maintenance in clinical medicine. 2004 , 117, 262-9	21
1459	Identification of differentially expressed genes in salivary gland tumors with cDNA microarray. 2004 , 31, 261-8	4
1458	Gene expression studies in lung development and lung stem cell biology. 2004 , 64, 57-71	4
1457	Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 2004 , 40, 205-11	204
1456	[The genetics of glioma: molecular classification]. 2004 , 33, 1268-73	1
1455	Dissecting the molecular mechanisms of human cancer: translating laboratory advances into clinical practice. 2004 , 2, 1-6	1

1454 E4. Gene expression profiles: What the clinicians need to know. **2004**, 2, 10-11

1453 Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. **2004**, 23, 1618-26

45

1452 Oncogenic aberrations of cullin-dependent ubiquitin ligases. **2004**, 23, 2037-49

67

1451 Biomedical marker molecules for cancer [Current status and perspectives. **2004**, 3, 228-237

6

1450 Genetic inheritance of gene expression in human cell lines. **2004**, 75, 1094-105

304

1449 Shaping the future: training of professionals for radiotherapy in Europe. **2004**, 70, 103-5

5

1448 Injury research in the genomic era. **2004**, 363, 2076-83

101

1447 Exceptional matters. **2004**, 364, 2142-51

12

1446 Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. **2004**, 64, 40-7

107

1445 Sophisticated radiotherapy with optimal surgery is the way forward. **2004**, 16, 529-35

1444 Ensemble Recordings Of Human Subcortical Neurons as a Source Of Motor Control Signals For a Brain-Machine Interface. **2004**, 55, 27-38

155

1443 Molecular Analysis and Genome Discovery. **2004**, 5, 609-610

1442 Expression genomics and cancer biology. **2004**, 5, 1117-28

4

1441 Challenges in breast cancer clinical trial design in the postgenomic era. **2004**, 16, 536-41

13

1440 Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. **2004**, 23, 321-9

34

1439 Pharmacogenomics. **2004**, 11, 211-20

32

1438 Exceptional matters: clinical research from bedside to bench. **2004**, 4, 551-66

9

1437 A three-layer multidatabase system for functional statistical analyses of microarray experiment results. **2004**, 2004, 2805-8

1436	Predicting drug response based on gene expression. 2004 , 51, 205-227	26
1435	Gene expression patterns, prognostic and diagnostic markers, and lung cancer biology. 2004 , 125, 111S-5S	13
1434	GOAL: automated Gene Ontology analysis of expression profiles. 2004 , 32, W492-9	36
1433	Review of: Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. 2004 , 7,	1
1432	Gene expression analysis of human renal biopsies: recent developments towards molecular diagnosis of kidney disease. 2004 , 13, 313-8	16
1431	Genetic, genomic, and bioinformatic tools for studying breast cancer progression. 2004 , 19, 83-91	1
1430	Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. 2004 , 4, 211-213	1
1429	Application of proteomics in the study of tumor metastasis. 2004 , 2, 152-66	22
1428	Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. 2004 , 1, 134-40	49
1427	The pathology of hereditary breast cancer. 2004 , 2, 131-8	16
1426	Increased measurement accuracy for sequence-verified microarray probes. 2004 , 18, 308-15	67
1425	A comparison of oligonucleotide and cDNA-based microarray systems. 2004 , 16, 361-70	97
1424	Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. 2004 , 286, L1095-104	73
1423	Genomics and clinical medicine: rationale for creating and effectively evaluating animal models. 2004 , 229, 866-75	33
1422	The Use of a Compendium of Expression Profiles for Mechanism of Toxicity Predictions. 2005 , 215-233	
1421	A Short Introduction to the Expression Profile Toolbox. 2005 , 45-53	
1420	Statistics for Toxicogenomics. 2005 , 115-145	
1419	Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. 2005 , 65, 3063-71	122

1418	The Mark Coventry Award: white blood cell gene expression: a new approach toward the study and diagnosis of infection. 2005 , 440, 38-44	47
1417	Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle. 2005 , 65, 7733-42	18
1416	Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. 2005 , 65, 3011-6	49
1415	Tumor heterogeneity affects the precision of microarray analysis. 2005 , 14, 65-71	14
1414	Gene expression analysis using filter cDNA microarrays. 2006 , 120, 415-24	2
1413	High-throughput scanning with single-molecule sensitivity. 2005 , 5699, 202	6
1412	Identifying site-specific metastasis genes and functions. 2005 , 70, 149-58	79
1411	Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?. 2005 , 17, 551-8	19
1410	Expression profiling of colon cancer cell lines and colon biopsies: towards a screening system for potential cancer-preventive compounds. 2005 , 14, 439-57	9
1409	Quantitative in situ cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis. 2005 , 2, 291-300	2
1408	Specialized DNA arrays for the differentiation of pancreatic tumors. 2005 , 11, 8048-54	41
1407	Clinical application of molecular profiling in breast cancer. 2005 , 1, 485-96	11
1406	Emerging approaches in molecular profiling affecting oncology drug discovery. 2005 , 70, 445-8	3
1405	Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. 2005 , 16, 1023-8	11
1404	Gene expression profiling of primary tumor cell populations using laser capture microdissection, RNA transcript amplification, and GeneChip microarrays. 2005 , 293, 187-207	15
1403	Systems Biology: Applications in Drug Discovery. 2005 , 123-183	14
1402	Integration of Microarray Data for a Comparative Study of Classifiers and Identification of Marker Genes. 2005 , 147-162	
1401	1 Identification of Tumor-Specific Genes. 2005 , 3-21	1

1400	Dissecting tBHQ induced ARE-driven gene expression through long and short oligonucleotide arrays. 2005 , 21, 43-58	14
1399	Genomics-based prognosis and therapeutic prediction in breast cancer. 2005 , 3, 291-300	47
1398	The potential of microarrays to assist shrimp breeding and production: a review. 2005 , 45, 901	4
1397	Statistical methods for gene expression analysis. 2005 ,	
1396	Tailored therapy of colorectal cancer: results, challenges and future directions. 2005 , 11, 175-88	3
1395	Bioinformatics Challenges and Opportunities. 2005 , 63-94	1
1394	Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. 2005 , 105, 301-7	183
1393	High Sensitivity Expression Profiling. 2005 , 229-250	1
1392	Apports des puces [^] ADN dans la comprhension de la polyarthrite rhumatoïde. 2005 , 72, 281-286	
1391	Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. 2005 , 62, 1035-9	126
1390	cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures. 2005 , 344, 92-101	24
1389	Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. 2005 , 77, 76-89	68
1388	Exploiting scale-free information from expression data for cancer classification. 2005 , 29, 288-93	3
1387	GeneMCL in microarray analysis. 2005 , 29, 354-9	10
1386	Application of expression genomics for predicting treatment response in cancer. 2005 , 1058, 186-95	9
1385	DNA microarrays: recent developments and applications to the study of pituitary tissues. 2005 , 28, 49-56	13
1384	Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. 2005 , 12, 166-77	7
1383	LARALink: a web application for cytogenetic linkage analysis. 2005 , 67, 314-21	3

1382	Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. 2005 , 13, 1311-20	170
1381	Genomic approaches in the management and treatment of breast cancer. 2005 , 92, 618-24	26
1380	Histopathologic indicators of breast cancer biology: insights from population mammographic screening. 2005 , 92, 1366-71	12
1379	Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. 2005 , 93, 406-11	15
1378	No common denominator for breast cancer lymph node metastasis. 2005 , 93, 924-32	78
1377	Probabilistic model of the human protein-protein interaction network. 2005 , 23, 951-9	338
1376	An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. 2005 , 37, 182-6	346
1375	Integrative analysis of the cancer transcriptome. 2005 , 37 Suppl, S31-7	385
1374	An integrative genomics approach to infer causal associations between gene expression and disease. 2005 , 37, 710-7	820
1373	Control of DNA replication and its potential clinical exploitation. 2005 , 5, 135-41	136
1372	The promise of genetically engineered mice for cancer prevention studies. 2005 , 5, 184-98	57
1371	Ovarian cancer metastasis: integrating insights from disparate model organisms. 2005 , 5, 355-66	427
1370	Breast cancer metastasis: markers and models. 2005 , 5, 591-602	1591
1369	Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. 2005 , 5, 735-43	249
1368	On the road to cancer: aneuploidy and the mitotic checkpoint. 2005 , 5, 773-85	903
1367	Biomarkers in cancer staging, prognosis and treatment selection. 2005 , 5, 845-56	1278
1366	How molecular profiling could revolutionize drug discovery. 2005 , 4, 345-50	104
1365	An array of problems. 2005 , 4, 362-3	57

1364	Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. 2005 , 24, 963-73	131
1363	Peripheral blood gene expression profiling in rheumatoid arthritis. 2005 , 6, 388-97	131
1362	A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. 2005 , 24, 869-79	7
1361	Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. 2005 , 24, 1244-51	154
1360	Identification of molecular apocrine breast tumours by microarray analysis. 2005 , 24, 4660-71	594
1359	Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. 2005 , 24, 6367-75	61
1358	Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. 2005 , 24, 6564-73	98
1357	Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. 2005 , 24, 7094-104	110
1356	Colon cancer prognosis prediction by gene expression profiling. 2005 , 24, 6155-64	83
1355	A quantitative genomic expression analysis platform for multiplexed in vitro prediction of drug action. 2005 , 5, 126-34	17
1354	Candidate-based proteomics in the search for biomarkers of cardiovascular disease. 2005 , 563, 23-60	298
1353	Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. 2005 , 85, 1040-50	177
1352	Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. 2005 , 18, 1165-75	57
1351	The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. 2005 , 18, 1305-20	125
1350	Genes that mediate breast cancer metastasis to lung. <i>Nature</i> , 2005 , 436, 518-24	50.4 2242
1349	Utilizing logical relationships in genomic data to decipher cellular processes. 2005 , 272, 5110-8	32
1348	The interface of genomic technologies and nursing. 2005 , 37, 111-9	16
1347	Gene expression profiling of breast cancer in ethnic populations: an aid to gene discovery for the benefit of all. 2005 , 11, 89-91	3

1346	Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. 2005 , 163, 44-56	49
1345	Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. 2005 , 7, 337-50	131
1344	The transcriptional repressor Snail promotes mammary tumor recurrence. 2005 , 8, 197-209	585
1343	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. 2005 , 8, 393-406	625
1342	Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs. 2005 , 29, 509-17	17
1341	Molecular requirements for epithelial-mesenchymal transition during tumor progression. 2005 , 17, 548-58	1505
1340	An automated procedure to properly handle digital images in large scale tissue microarray experiments. 2005 , 79, 197-208	13
1339	Gelatinase-mediated migration and invasion of cancer cells. 2005 , 1755, 37-69	269
1338	The oligometastatic state in breast cancer: hypothesis or reality. 2005 , 14, 87-93	50
1337	Histopathology of primary breast cancer 2005. 2005 , 14, 487-92	15
1336	Preoperative (neoadjuvant) systemic treatment of breast cancer. 2005 , 14, 576-81	29
1335	When will more useful predictive factors be ready for use?. 2005 , 14, 617-23	16
1334	Adjuvant chemotherapy for breast cancer--"one fits all"?. 2005 , 14, 564-9	7
1333	Prognostic and predictive factors revisited. 2005 , 14, 493-9	85
1332	Determination of tumour marker genes from gene expression data. 2005 , 10, 429-37	27
1331	The transcriptome's drugable frequenters. 2005 , 10, 857-64	13
1330	Gene Expression Profiling Predicts Therapeutic Response and Prognosis in Patients with Breast Cancer. 2005 , 6, 199-201	
1329	Surgical application of cDNA microarray technique. 2005 , 138, 399-403	

1328 HypothesisFact or Fiction?. **2005**, 138, 403

1327 Molecular changes in prostatic cancer. **2005**, 14, 91-104

10

1326 Tumor cells caught in the act of invading: their strategy for enhanced cell motility. **2005**, 15, 138-45

224

1325 Breast cancer: integrating the patient with her genome. **2005**, 23, 3-5

1324 Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. **2005**, 575, 17-33

51

1323 In pursuit of effective toxicogenomics. **2005**, 575, 4-16

14

1322 Cancer: undifferentiation or specialization?. **2005**, 41, 655-6

1321 Bringing molecular prognosis and prediction to the clinic. **2005**, 6, 61-76

30

1320 Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. **2005**, 6, 315-24

6

1319 Signal transduction pathway profiling of individual tumor samples. **2005**, 6, 163

31

1318 Storing, linking, and mining microarray databases using SRS. **2005**, 6, 192

10

1317 `stam`--a Bioconductor compliant R package for structured analysis of microarray data. **2005**, 6, 211

2

1316 Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. **2005**, 6, 265

146

1315 In silico microdissection of microarray data from heterogeneous cell populations. **2005**, 6, 54

60

1314 An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. **2005**, 6 Suppl 4, S7

25

1313 Gene expression signature of estrogen receptor alpha status in breast cancer. **2005**, 6, 37

114

1312 Three microarray platforms: an analysis of their concordance in profiling gene expression. **2005**, 6, 63

83

1311 Numbers of mutations to different types of colorectal cancer. **2005**, 5, 126

12

1310	Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. 2005 , 5, 45	113
1309	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. 2005 , 96, 684-94	93
1308	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. 2005 , 114, 139-43	87
1307	Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. 2005 , 114, 963-8	30
1306	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. 2005 , 116, 340-50	443
1305	Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. 2005 , 117, 961-73	62
1304	Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. 2005 , 117, 934-41	14
1303	The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. 2005 , 103, 884-91	146
1302	Microarray technology for surgeons. 2005 , 92, 387-8	1
1301	Overview of Microarrays in Genomic Analysis. 2005 , 127-165	
1300	Introduction to DNA Microarray Technology. 2005 , 1-15	
1299	References. 2005 , 152-182	
1298	Lymph node staging surgery and breast cancer: potholes in the fast lane from more to less. 2005 , 89, 53-60	3
1297	Contemporary management of penile squamous cell carcinoma. 2005 , 89, 43-50	51
1296	Follicular thyroid lesions, elements that affect both diagnosis and prognosis. 2005 , 89, 108-13	36
1295	Estrogen signaling and prediction of endocrine therapy. 2005 , 56 Suppl 1, 27-31	12
1294	Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. 2005 , 16, 120-6	33
1293	Adaptor-tagged competitive polymerase chain reaction: amplification bias and quantified gene expression levels. 2005 , 339, 15-28	7

1292	The coefficient of intrinsic dependence (feature selection using el CID). 2005 , 38, 623-636	17
1291	Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. 2005 , 48, 2238-48	25
1290	p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. 2005 , 447, 688-94	177
1289	«Cancers du sein». 2005 , 7, 342-379	12
1288	Protocole temporaire de traitement Trastuzumab (Herceptin®) en situation adjuvante. 2005 , 7, s86-s99	
1287	Lymphatic staging in colorectal cancer: pathologic, molecular, and sentinel node techniques. 2005 , 48, 371-83	15
1286	Mammakarzinom Standards der Versorgung heute und morgen. 2005 , 11, 265-272	1
1285	Internationale Konferenz St. Gallen 26-29.01.2005: Primary Therapy of Early Breast Cancer 2005 , 11, 446-456	
1284	Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. 2005 , 11, 873-888	
1283	Vers de nouveaux tests biologiques pour prédire le potentiel métastatique d'un cancer. 2005 , 17, 30-33	
1282	Utilizing prognostic and predictive factors in breast cancer. 2005 , 6, 147-59	47
1281	Gene expression profiling of primary breast cancer. 2005 , 7, 38-44	15
1280	Maintenance of cell type diversification in the human breast. 2005 , 10, 61-74	13
1279	Non-angiogenic functions of VEGF in breast cancer. 2005 , 10, 283-90	63
1278	Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells. 2005 , 72, 35-46	9
1277	Prognostic factors affecting the natural history of node-negative breast cancer. 2005 , 89, 35-45	38
1276	Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. 2005 , 90, 5-14	135
1275	Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. 2005 , 90, 15-23	180

1274	The "portrait" of hereditary breast cancer. 2005 , 89, 297-304	42
1273	BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. 2005 , 91, 179-86	143
1272	The future of breast cancer: the role of prognostic factors. 2005 , 89 Suppl 1, S17-26	25
1271	Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. 2005 , 94, 205-11	14
1270	Abstracts of the 10th International Congress of the Metastasis Research Society, Genoa, Italy, 17-20 September 2004. 2005 , 21, 599-662	
1269	Metastasis predictive signature profiles pre-exist in normal tissues. 2005 , 22, 593-603	94
1268	A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. 2005 , 5, 22	87
1267	Prognostic index in lobular breast cancer. 2005 , 10, 165-172	1
1266	Molecular evolution of breast cancer. 2005 , 205, 248-54	391
1265	Hunting the primary: novel strategies for defining the origin of tumours. 2005 , 205, 236-47	22
1264	Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. 2005 , 205, 123-9	115
1263	TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. 2005 , 207, 14-9	7
1262	FDR-controlling testing procedures and sample size determination for microarrays. 2005 , 24, 2267-80	46
1261	BeadArray-based solutions for enabling the promise of pharmacogenomics. 2005 , 39, S583-8	23
1260	Classification and selection of biomarkers in genomic data using LASSO. 2005 , 2005, 147-54	79
1259	Analysis of Neural Precursor Cells in the Context of Origin of Brain Tumors, Their Treatment, and Repair of Treatment-Associated Damage. 2005 , 107-123	
1258	Expression profiling using cDNA microarrays. 2006 , 120, 403-14	3
1257	Prognostische Faktoren und Evaluationskriterien. 2005 , 59-66	

- 1256 DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. **2005**, 241, 16-26 29
- 1255 Strategy for gene expression-based biomarker discovery. **2005**, Suppl, 25-9 3
- 1254 . **2005**, 3
- 1253 Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. **2005**, 77-100 1
- 1252 References. **2005**, 145-164
- 1251 Integrating genotypic, molecular profiling, and clinical data to elucidate common human diseases. **2005**,
- 1250 Microarray CGH. **2005**,
- 1249 Microarray analysis and RNA silencing to determine genes functionally important in mesothelioma. **2005**, 447-469
- 1248 Clinomics: Postgenomic Cancer Care. **2005**, 341-358
- 1247 Technologies for systematic analysis of eukaryotic transcriptomes. **2005**,
- 1246 Gene Expression Data and Survival Analysis. **2005**, 21-34 2
- 1245 Use of extreme patient samples for outcome prediction from gene expression data. **2005**, 21, 3377-84 23
- 1244 Gene expression profile predicts patient survival of gastric cancer after surgical resection. **2005**, 23, 7286-95 111
- 1243 Distinct molecular portraits of human failing hearts identified by dedicated cDNA microarrays. **2005**, 7, 157-65 27
- 1242 Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. **2005**, 65, 5607-19 64
- 1241 DNA microarrays in clinical cancer research. **2005**, 5, 111-20 42
- 1240 Gene profile and response to treatment. **2005**, 16 Suppl 2, ii195-202 11
- 1239 Expression genomics and drug development: towards predictive pharmacology. **2005**, 3, 303-21 7

1238	Analysis of recursive gene selection approaches from microarray data. 2005 , 21, 3741-7	77
1237	Gene expression profiling of the irinotecan pathway in colorectal cancer. 2005 , 11, 2053-62	52
1236	From traditional biomarkers to transcriptome analysis in drug development. 2005 , 5, 29-38	34
1235	Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. 2005 , 5, 83-102	31
1234	Discovering molecular functions significantly related to phenotypes by combining gene expression data and biological information. 2005 , 21, 2988-93	90
1233	Mammary cancer and social interactions: identifying multiple environments that regulate gene expression throughout the life span. 2005 , 60 Spec No 1, 32-41	65
1232	Comparative functional genomics for identifying models of human cancer. 2005 , 26, 1013-20	51
1231	Personalized diagnostic and therapeutic strategies in oncology. 2005 , 2, 97-110	1
1230	Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?. 2005 , 7, 380-9	57
1229	Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. 2005 , 5, 385-95	25
1228	New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. 2005 , 16 Suppl 2, ii191-4	21
1227	Hotelling's T2 multivariate profiling for detecting differential expression in microarrays. 2005 , 21, 3105-13	75
1226	Survivin, other IAPs, Smac/Diablo, and Omi/Htra2 [Modulation of the Advancing Apoptotic Process. 2005 , 137-155	1
1225	Predicting cancer susceptibility from single-nucleotide polymorphism data. 2005 ,	28
1224	Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. 2005 , 23, 7265-77	461
1223	Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. 2005 , 11, 8623-31	173
1222	Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. 2005 , 23, 3331-42	138
1221	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. 2005 , 65, 4059-66	212

1220	BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. 2005 , 65, 10692-9	157
1219	Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. 2005 , 11, 2962-8	141
1218	From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. 2005 , 102, 11651-6	306
1217	Ensemble dependence model for classification and prediction of cancer and normal gene expression data. 2005 , 21, 3114-21	28
1216	A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. 2005 , 14, 1108-12	159
1215	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. 2005 , 102, 13550-5	999
1214	Bayesian model averaging: development of an improved multi-class, gene selection and classification tool for microarray data. 2005 , 21, 2394-402	203
1213	DIG--a system for gene annotation and functional discovery. 2005 , 21, 2957-9	1
1212	Brain Tumors. 2005 ,	9
1211	How many samples are needed to build a classifier: a general sequential approach. 2005 , 21, 63-70	22
1210	Gene expression profiling of breast cancer: a new tumor marker. 2005 , 23, 1631-5	126
1209	Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. 2005 , 65, 9695-704	46
1208	Molecular decomposition of complex clinical phenotypes using biologically structured analysis of microarray data. 2005 , 21, 1971-8	34
1207	Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. 2005 , 11, 2156-62	132
1206	Circulating and disseminated tumor cells. 2005 , 23, 1623-6	107
1205	Estimating misclassification error with small samples via bootstrap cross-validation. 2005 , 21, 1979-86	102
1204	The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination. 2005 , 4, 1719-21	10
1203	Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. 2005 , 19, 574-87	107

1202	Gene expression profiling in human cardiovascular disease. 2005 , 43, 696-701	11
1201	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. 2005 , 65, 11259-64	221
1200	Tumor markers in breast cancer- European Group on Tumor Markers recommendations. 2005 , 26, 281-93	246
1199	Microarray Technology and Its Applications. 2005 ,	30
1198	Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. 2005 , 10, 258-94	35
1197	Contralateral breast cancer: where does it all begin?. 2005 , 23, 4585-7	6
1196	Testing association of a pathway with survival using gene expression data. 2005 , 21, 1950-7	122
1195	Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. 2005 , 175, 7837-47	95
1194	Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. 2005 , 26, 1343-53	91
1193	The sensitivity and specificity of markers for event times. 2006 , 7, 182-97	51
1192	[Treatment results following breast-conserving therapy in primary breast cancer]. 2005 , 127, 31-6	
1191	Microarrays: applications and pitfalls. 2005 , 62, 1669-72	23
1190	Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. 2005 , 19, 1543-54	93
1189	A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. 2005 , 21, 3025-33	58
1188	A protocol for building and evaluating predictors of disease state based on microarray data. 2005 , 21, 3755-62	111
1187	Screening of tissue microarrays for ubiquitin proteasome system components in tumors. 2005 , 399, 334-55	5
1186	Breast cancer gene expression profiling: clinical trial and practice implications. 2005 , 6, 49-58	10
1185	Prognostic factors for breast cancer and their use in the clinical setting. 2005 , 5, 269-81	7

1184	Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer. 2005 , 353, 617-22	2
1183	Inhibition of angiogenesis in cancer patients. 2005 , 10, 403-12	16
1182	Prognostic relevance of basal cytokeratin expression in operable breast cancer. 2005 , 69, 478-85	83
1181	Genetic profiling of human hepatocellular carcinoma. 2005 , 25, 125-32	46
1180	Gene expression profiling for pharmaceutical safety assessment. 2005 , 1, 247-60	9
1179	Gene expression profiling to characterize anticancer drug sensitivity. 2005 , 111, 197-231	
1178	Optimized Kernel Machines for Cancer Classification Using Gene Expression Data. 2005 ,	0
1177	GAVis: a Tool for Visualization and Control of Genetic Algorithms for -omic Data Analysis. 2005 , 2005, 2855-8	
1176	Modern approaches to age-old questions about thyroid tumors. 2005 , 15, 575-82	7
1175	Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. 2005 , 15, 562-8	29
1174	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. 2005 , 5, 1069-83	44
1173	Utility of high dimensional genomic composite biomarkers in therapeutic and/or diagnostic development.	1
1172	Death-from-cancer signatures and stem cell contribution to metastatic cancer. 2005 , 4, 1171-5	98
1171	TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. 2005 , 16, 1987-2002	460
1170	Discovery of highly differentiative gene groups from microarray gene expression data using the gene club approach. 2005 , 3, 1263-80	16
1169	Epidemiology informing clinical practice: from bills of mortality to population laboratories. 2005 , 2, 625-34	16
1168	Differential gene expression profiles in stage I primary biliary cirrhosis. 2005 , 100, 2019-30	24
1167	Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. 2005 ,	5

1166	A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling. 2005 , 280, 40301-9	147
1165	Prediction of docetaxel response in human breast cancer by gene expression profiling. 2005 , 23, 422-31	237
1164	Targeted drug delivery in cancer therapy. 2005 , 4, 363-74	214
1163	SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. 2005 , 25, 3421-30	34
1162	Limits of predictive models using microarray data for breast cancer clinical treatment outcome. 2005 , 97, 927-30	104
1161	Validation of microarray data by quantitative reverse-transcriptase polymerase chain reaction. 2005 , 23, 9439-40; author reply 9440	5
1160	Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. 2005 , 280, 12935-43	35
1159	Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. 2005 , 11, 4003-11	143
1158	GEPAS, an experiment-oriented pipeline for the analysis of microarray gene expression data. 2005 , 33, W616-20	79
1157	Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. 2005 , 65, 4530-43	49
1156	Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. 2005 , 65, 8166-73	52
1155	Prediction of radiation sensitivity using a gene expression classifier. 2005 , 65, 7169-76	155
1154	Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. 2005 , 102, 3738-43	823
1153	Gene expression profiling of chemically induced rat mammary gland cancer. 2005 , 26, 503-9	21
1152	Robust Ensemble Learning for Cancer Diagnosis Based on Microarray Data Classification. 2005 , 564-574	1
1151	Gene expression profiling in acute myeloid leukemia. 2005 , 23, 6296-305	84
1150	Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. 2005 , 4, 361-8	76
1149	Optimal number of features as a function of sample size for various classification rules. 2005 , 21, 1509-15	220

1148	A weighted nearest mean classifier for sparse subspaces.	2
1147	An Introduction to MAMA (Meta-Analysis of MicroArray data) System. 2005 , 2005, 7730-3	4
1146	Genomic profiling of cancer: what next?. 2005 , 23, 7253-6	10
1145	Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. 2005 , 23, 732-40	283
1144	Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. 2005 , 65, 5172-80	73
1143	A molecular signature in superficial bladder carcinoma predicts clinical outcome. 2005 , 11, 4029-36	123
1142	Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. 2005 , 11, 3184-90	74
1141	Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. 2005 , 3, 203-18	68
1140	An integrated feature selection and classification method to select minimum number of variables on the case study of gene expression data. 2005 , 3, 1107-36	9
1139	Tissue inhibitor of metalloproteinases-1 in breast cancer. 2005 , 12, 215-27	95
1138	Identification of RAI3 as a therapeutic target for breast cancer. 2005 , 12, 65-73	37
1137	Bladder cancer outcome and subtype classification by gene expression. 2005 , 11, 4044-55	266
1136	Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. 2005 , 3, 71-7	22
1135	Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. 2005 , 23, 2996-3000	27
1134	DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy. 2005 , 3, 289-304	8
1133	A gene expression signature for relapse of primary wilms tumors. 2005 , 65, 2592-601	50
1132	FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. 2005 , 65, 11304-13	67
1131	Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. 2005 , 10, 370-81	130

1130	Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. 2005 , 16, 735-42	43
1129	Effects of threshold choice on biological conclusions reached during analysis of gene expression by DNA microarrays. 2005 , 102, 8961-5	83
1128	Superior feature-set ranking for small samples using bolstered error estimation. 2005 , 21, 1046-54	37
1127	M@CBETH: a microarray classification benchmarking tool. 2005 , 21, 3185-6	13
1126	Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. 2005 , 97, 1238-9	12
1125	Effects of RNA degradation on gene expression analysis of human postmortem tissues. 2005 , 19, 1356-8	90
1124	Gene-expression profiling and the future of adjuvant therapy. 2005 , 10 Suppl 2, 30-4	53
1123	A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings. 2005 , 102, 14854-9	39
1122	Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. 2005 , 65, 1376-83	58
1121	Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. 2005 , 10, 86-103	1001
1120	SVM ensembles for selecting the relevant feature subsets.	1
1119	Tumor profiling turmoil. 2005 , 4, 659-60	6
1118	In silico identification of breast cancer genes by combined multiple high throughput analyses. 2005 , 15, 205	0
1117	Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. 2005 , 26, 329	4
1116	Aberrant expressions of annexin A10 short isoform, osteopontin and Fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. 2005 , 26, 1053	2
1115	Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. 2005 , 27, 371	2
1114	How to best classify breast cancer: Conventional and novel classifications (Review). 2005 , 27, 1307	3
1113	Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. 2005 , 16, 11	3

1112	Time-dependent RNA degradation affecting cDNA array quality in spontaneous canine tumours sampled using standard surgical procedures. 2005 , 16, 979	
1111	Embracing complexity, inching closer to reality. 2005 , 2005, pe40	35
1110	Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. 2005 , 11, 6226-32	32
1109	Prediction of cancer outcome with microarrays: a multiple random validation strategy. 2005 , 365, 488-92	815
1108	Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. 2005 , 365, 671-9	2172
1107	Gene-expression profiling in breast cancer. 2005 , 365, 634-5	31
1106	Prediction of cancer outcome with microarrays. 2005 , 365, 1683; author reply 1684-5	12
1105	Breast cancer. 2005 , 365, 1727-41	346
1104	Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. 2005 , 6, 142	35
1103	Current and future pathological examination in breast cancer. 2005 , 3, 121-130	
1102	Gene Array Technologies in Biological Investigations. 2005 , 93, 737-749	2
1101	Bioinformatics in otolaryngology. 2005 , 38, 321-32, vii	1
1100	Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. 2005 , 11, 5381-9	340
1099	Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. 2005 , 23, 7350-60	696
1098	The Importance of Validation in Genomic Studies of Breast Cancer. 2005 , 16, 16-19	
1097	Beyond lymph node staging: molecular predictors of outcome in breast cancer. 2005 , 14, 69-84, vi	1
1096	Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy. 2005 , 7, 91-8	9
1095	Advances in Bioinformatics and Computational Biology. 2005 ,	3

1094	Medical Biomethods Handbook. 2005 ,	2
1093	Molecular targets of growth, differentiation, tissue integrity, and ectopic cell death in cancer cells. 2005 , 20, 579-88	9
1092	Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors. 2005 , 12, 534-44	24
1091	Adoption of array technologies into the clinical laboratory. 2005 , 5, 409-20	18
1090	Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. 2005 , 65, 9155-8	264
1089	A Genetic Algorithm Approach for Discovering Diagnostic Patterns in Molecular Measurement Data. 2005 ,	7
1088	Gene Selection via a Spectral Approach.	
1087	Pathology of the Future: Molecular Profiling for Targeted Therapy. 2005 , 23, 36-46	58
1086	Microarrays and Crohn's disease: collecting reliable information. 2005 , 40, 369-77	8
1085	Identifying simple discriminatory gene vectors with an information theory approach. 2005 , 13-24	2
1084	Mining the tumor phosphoproteome for cancer markers. 2005 , 11, 3163-9	74
1083	Multivariate gene selection: does it help?.	
1082	Platelet genomics and proteomics in human health and disease. 2005 , 115, 3370-7	120
1081	Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. 2005 , 2, 246-54	77
1080	Discovery of gene expression patterns across multiple cancer types.	
1079	Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. 2005 , 4, 1799-804	56
1078	Molecular staging for survival prediction of colorectal cancer patients. 2005 , 23, 3526-35	285
1077	Genomic medicine: genetic variation and its impact on the future of health care. 2005 , 360, 1543-50	50

1076	Efficiently searching the important input variables using Bayesian discriminant. 2005 , 52, 785-793	11
1075	Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. 2005 , 4, 674-89	31
1074	Missing value estimation for DNA microarray gene expression data: local least squares imputation. 2005 , 21, 187-98	314
1073	Cancer epigenetics. 2005 , 14 Spec No 1, R65-76	384
1072	Advances in toxicogenomics. 2005 , 18, 403-14	50
1071	Scaling of True and Apparent ROC AUC with Number of Observations and Number of Variables. 2005 , 34, 771-781	5
1070	Outcome signature genes in breast cancer: is there a unique set?. 2005 , 21, 171-8	622
1069	The evolving portrait of cancer metastasis. 2005 , 70, 291-7	70
1068	Advances in Targeted Cancer Therapy. 2005 ,	
1067	A history of microarrays in biomedicine. 2005 , 5, 315-28	26
1066	Improved representation of gene markers on microarray by PCR-Select subtracted cDNA targets. 2005 , 137, 110-8	4
1065	Investigations into the molecular background of endometrial cancer. 2005 , 1279, 149-153	
1064	Logical networks inferred from highly specific discovery of transcriptionally regulated genes predict protein states in cultured gliomas. 2005 , 336, 1278-84	7
1063	Mechanisms of cancer cell invasion. 2005 , 15, 87-96	388
1062	Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations. 2005 , 11, 390-399	10
1061	PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. 2005 , 120, 303-13	676
1060	The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. 2005 , 122, 835-47	281
1059	Taxanes in the treatment of early breast cancer. 2005 , 31, 618-27	29

1058	Endostatin: the logic of antiangiogenic therapy. 2005 , 8, 59-74	91
1057	Metastases and their microenvironments: linking pathogenesis and therapy. 2005 , 8, 247-57	24
1056	Tailoring Ras-pathway--inhibitor combinations for cancer therapy. 2005 , 8, 369-80	50
1055	Molecular markers of prostate cancer outcome. 2005 , 41, 858-87	153
1054	Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. 2005 , 41, 2760-8	37
1053	Growth factors and their relationship to neoplastic and paraneoplastic disease. 2005 , 16, 83-94	3
1052	Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. 2005 , 87, 287-97	225
1051	Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. 2005 , 167, 1125-37	27
1050	Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 2005 , 166, 1205-16	41
1049	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. 2005 , 86, 127-41	218
1048	[Molecular alterations in breast cancer: clinical implications and new analytical tools]. 2005 , 26, 470-8	3
1047	The Oncogenetic Basis of Breast Cancer. 2005 , 15-26	
1046	Molecular, Cellular, and Developmental Biology of Breast Cancer. 2005 , 27-41	
1045	Molecular Pathology Assays for Breast Cancer. 2005 , 145-168	
1044	Discovering causes and cures for cancer from gene expression analysis. 2005 , 4, 548-63	11
1043	Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. 2005 , 3, 32	39
1042	Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. 2005 , 75, 252-7	70
1041	Brain metastases of breast cancer. 2005 , 5, 253-68	8

1040	Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. 2005 , 11, 2612-9	57
1039	Roadmap for developing and validating therapeutically relevant genomic classifiers. 2005 , 23, 7332-41	324
1038	Applications of DNA microarrays in biology. 2005 , 74, 53-82	309
1037	cDNA Microarrays. 2005 , 255-271	
1036	RFID Technology and Electronic Tags to Identify Cryopreserved Materials. 2005 , 3, 112-115	6
1035	Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. 2005 , 129, 66-73	110
1034	Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. 2005 , 39, 39-51	31
1033	Genome-wide views of cancer metastasis. 2005 , 2, 165-169	4
1032	Models of epithelial-mesenchymal transition. 2005 , 2, 57-63	24
1031	Utility of microarrays in the management of breast cancer patients. 2005 , 2, 307-311	
1030	Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003. 2005 , 156, 227-40	23
1029	A novel method for generation of signature networks as biomarkers from complex high throughput data. 2005 , 158, 20-9	120
1028	Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. 2005 , 12, 903-16	65
1027	Complex diseases in gastroenterology and hepatology: GERD, Barrett's, and esophageal adenocarcinoma. 2005 , 3, 529-37	21
1026	The promise of gene signatures in cancer diagnosis and prognosis. 2005 ,	
1025	The great escape: when cancer cells hijack the genes for chemotaxis and motility. 2005 , 21, 695-718	291
1024	Genomics in breast cancer-therapeutic implications. 2005 , 2, 26-33	41
1023	Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies. 2005 , Chapter 13, Unit 13.1	23

1022	Breast cancer biomarkers. 2005 , 40, 99-125	17
1021	Molecular Biology of Human Cancers. 2005 ,	4
1020	Molecular mechanisms in gliomagenesis. 2005 , 94, 1-27	55
1019	Laser Capture Microdissection. 2005 ,	11
1018	Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. 2005 , 7, R1005-16	38
1017	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. 2005 , 7, R1186-98	164
1016	Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. 2005 , 7, R953-64	597
1015	Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. 2005 , 7, R634-44	93
1014	The promise of microarrays in the management and treatment of breast cancer. 2005 , 7, 100-4	20
1013	Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. 2005 , 7, 96-9	22
1012	Show me the genes - I will tell you who/how to treat!. 2005 , 7, 77-9	5
1011	Outcome signature genes in breast cancer: is there a unique set?. 2005 , 7, 1	5
1010	Role of translational studies in optimizing palliative chemotherapy. 2005 , 7, 1	1
1009	Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit. 2005 , 7, 1	78
1008	The role of Xeloda in metastatic breast cancer. 2005 , 7, 1	78
1007	SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma. 2005 , 7, 1	78
1006	New agents for bone metastasis. 2005 , 7, 1	78
1005	Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node. 2005 , 7, 1	78

1004	Clinical profile and management of bilateral breast cancer. 2005 , 7, 1	2
1003	Nanoparticulate paclitaxel loaded into sterically stabilized mixed phospholipid micelles to improve chemotherapy of breast cancer. 2005 , 7, 1	1
1002	Breast cancer-screening programme amongst unprivileged women in Charleroi (Hainaut), Belgium. 2005 , 7, 1	78
1001	The role of gene expression profiling by microarray analysis for prognostic classification of breast cancer. 2005 , 7, 1	2
1000	A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC). 2005 , 7, 1	78
999	Methods for gene expression profiling in clinical trials for breast cancer. 2005 , 7, 1	78
998	Expression of c-met gene in invasive ductal carcinomas. 2005 , 7, 1	78
997	Simultaneous breast reconstruction. 2005 , 7, 1	78
996	Chemoprevention: beyond tamoxifen. 2005 , 7, 1	78
995	Tamoxifen resistance and adjuvant hormone therapy. 2005 , 7, 1	78
994	Adjuvant chemotherapy for operable breast cancer: old vs new schema. 2005 , 7, 1	78
993	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. 2005 , 7, 1	78
992	Cyclo-oxygenase-2 expression is associated with poor clinical outcome after doxorubicin-based chemotherapy in node-positive breast cancer: integration of tissue microarray. 2005 , 7, 1	78
991	Fibroadenoma of breast in Iranian women between 1994 and 2004. 2005 , 7, 1	78
990	Adjuvant radiotherapy after surgery in breast cancer: evaluation of acute toxicity. 2005 , 7, 1	78
989	6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits the growth of MCF-7 cells via inhibition of angiogenesis and hypoxia inducible factor alpha. 2005 , 7, 1	1
988	A performance study of different soft-computing procedures for automatic detection of breast cancer malignancy. 2005 , 7, 1	78
987	Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer. 2005 , 7, 1	2

986	The role of magnetic resonance imaging as an imaging tool to assess disease status and residual disease in locally advanced breast cancer. 2005, 7, 1	78
985	The axillary study with ultrasound and cytological puncture with fine needle in invasive breast cancer.. 2005, 7, 1	78
984	Gene expression profile-based predictors of response to chemotherapy. 2005, 7, 1	78
983	Minimal residual disease (MRD) in the bone marrow in ER-positive primary breast cancer patients. 2005, 7, 1	78
982	[ASCRIT] Antisense chemoradioimmunotherapy consisting of anti-POEM (Arg-Gly-Asp) scFv linked onto high-energy radioisotopes, vinorelbine-tartrate and 21-nucleotide double-stranded siRNA targeted to DNMT1 induce apoptosis in metastatic breast cancer (MBC) characterized by hypermethylated p53, p16, RASSF1A, RAR- β 2, BRCA2, H1C1, ESRI1, CDH1, Trbeta1, GSTP1, CCND2 and overexpression of bcl-2, cdc25c, Raf-1 and R11 integrin. 2005, 7, 1	78
981	Simultaneous reconstructive surgery for radical mastectomy. 2005, 7, 1	78
980	Preoperative hormonal therapy: results and implications. 2005, 7, 1	1
979	Radiotherapy in early stage invasive breast cancer: current tendencies. 2005, 7, 1	1
978	Neoadjuvant treatment: the MD Anderson experience. 2005, 7, 1	78
977	Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC). 2005, 7, 1	78
976	The roles of PET and CT/PET as preoperative studies. 2005, 7, 1	78
975	Present situation and future of genetic profiling for prognosis and treatment. 2005, 7, 1	78
974	Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer. 2005, 7, 1	1
973	Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients. 2005, 7, 1	78
972	Primary chemotherapy for operable breast cancer: the NSABP experience. 2005, 7, 1	4
971	Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial. 2005, 7, 1	78
970	Targeting the right chemotherapy for the right patient. 2005, 7, 1	1
969	Oral vinorelbine in metastatic breast cancer. 2005, 7, 1	2

968	Partial breast irradiation: why and how. 2005 , 7, 1	6
967	Erratum to: Multiclass classification of microarray data with repeated measurements: application to cancer. 2005 , 6, 405	2
966	Predicting the sites of metastases. 2005 , 6, 241	8
965	L2L: a simple tool for discovering the hidden significance in microarray expression data. 2005 , 6, R81	101
964	A DNA microarray survey of gene expression in normal human tissues. 2005 , 6, R22	172
963	Genomic analysis of early murine mammary gland development using novel probe-level algorithms. 2005 , 6, R20	17
962	Measuring proliferation in breast cancer: practicalities and applications. 2006 , 8, 216	139
961	GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. 2006 , 8, R64	24
960	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. 2006 , 8, R66	108
959	CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. 2006 , 8, R59	716
958	Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. 2006 , 8, R58	107
957	Predicting a local recurrence after breast-conserving therapy by gene expression profiling. 2006 , 8, R62	163
956	Classification of ductal carcinoma in situ by gene expression profiling. 2006 , 8, R61	128
955	When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?. 2006 , 8, 302	1
954	Breast cancer prognosis by combinatorial analysis of gene expression data. 2006 , 8, R41	49
953	Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. 2006 , 8, R38	179
952	Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. 2006 , 8, R51	14
951	Array-CGH and breast cancer. 2006 , 8, 210	62

950	The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. 2006 , 8, R32	56
949	A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. 2006 , 8, R25	387
948	Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. 2006 , 8, R23	150
947	Dissection of a metastatic gene expression signature into distinct components. 2006 , 7, R117	34
946	Classification methods for the development of genomic signatures from high-dimensional data. 2006 , 7, R121	17
945	A consensus prognostic gene expression classifier for ER positive breast cancer. 2006 , 7, R101	75
944	Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. 2006 , 7, R28	98
943	Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. 2006 , 8, R47	39
942	Nutrient-gene interactions and their role in complex diseases in dogs. 2006 , 228, 1513-20	4
941	Bioinformatics and Drug Discovery. 2006 ,	1
940	Evolving Intelligent Systems: Methods, Learning, & Applications. 2006 ,	27
939	Improving Treatment of Early Breast Cancer. 2006 , 4, 14-16	
938	Cancer du sein. 2006 ,	
937	Breast Cancer and Molecular Medicine. 2006 ,	2
936	Breast Cancer Research Protocols. 2006 ,	2
935	Biomarkers in Breast Cancer. 2006 ,	3
934	Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. 2006 , 8, 925-32	86
933	Histopathologic and Metabolic Criteria for Assessment of Treatment Response in Breast Cancer. 2006 , 1, 83-94	

932	Cancer Drug Resistance. 2006,	17
931	Biomarqueurs tissulaires tumoraux. Cancer du sein. Facteurs pronostiques, facteurs prdictifs. Quels standards en 2005 ?. 2006, 83-130	
930	Beyond linker histones and high mobility group proteins: global profiling of perchloric acid soluble proteins. 2006, 5, 925-34	17
929	Profils d'expression gnhique et Puces ^ADN dans le cancer du sein : choix du patient, choix du protocole. 2006, 267-276	
928	DNA repair pathway profiling and microsatellite instability in colorectal cancer. 2006, 12, 5104-11	31
927	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. 2006, 98, 15-25	233
926	Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. 2006, 44, 1082-7	25
925	Microarray Gene Expression Classification Based on Supervised Learning and Similarity Measures. 2006,	1
924	Significance of gene ranking for classification of microarray samples. 2006, 3, 312-20	37
923	Advances in Health care Technology Care Shaping the Future of Medical. 2006,	7
922	Prevention and Treatment of Age-related Diseases. 2006,	2
921	Locoregional therapy of breast cancer: maximizing control, minimizing morbidity. 2006, 6, 1281-99	1
920	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. 2006, 8, 214	25
919	ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. 2006, 34, D613-6	47
918	Fast and sensitive analysis of DNA hybridization in a PDMS micro-fluidic channel using fluorescence resonance energy transfer. 2006, 1509-11	29
917	Mechanisms of transcoelomic metastasis in ovarian cancer. 2006, 7, 925-34	320
916	Adenopatâ axilar de primario oculto. Manejo clnico. 2006, 49, 316-328	1
915	Molecular classification of breast tumors: toward improved diagnostics and treatments. 2007, 360, 91-114	50

914	The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. 2006 , 313, 1929-35	3392
913	Molecular biology of bladder cancer: prognostic and clinical implications. 2006 , 5, 67-77	43
912	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. 2006 , 98, 262-72	1485
911	Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. 2006 , 59, 1254-60	34
910	Current and future directions for adjuvant chemotherapy in early-stage breast cancer. 2006 , 4, 14-20	1
909	Conclusions. 2006 , 4, 21-23	
908	Current and future directions in early breast cancer therapy. 2006 , 4, 12-16	
907	Host genetics influence tumour metastasis. 2006 , 6, 141-6	105
906	. 2006 , 94, 692-709	5
905	Fully-automated detection of cerebral water content changes: study of age- and gender-related H2O patterns with quantitative MRI. 2006 , 29, 910-22	92
904	Exploring the human genome in cancer with genomic approaches. 2006 , 17, 1225-33	6
903	Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. 2006 , 66, 11954-66	197
902	The molecular biology of pulmonary metastasis. 2006 , 16, 115-24	23
901	A Molecular Profiling of Breast Cancer. 2006 , 9, 19-24	2
900	Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. 2006 , 7, 372-9	24
899	Heterogeneity of mammary lesions represent molecular differences. 2006 , 6, 275	29
898	A systems approach to clinical oncology: focus on breast cancer. 2006 , 4, 5	37
897	Prognostic factors in prostate cancer. 2006 , 1, 4	56

896	Molecular markers of multiple drug resistance in breast cancer. 2006 , 52, 125-9	24
895	Lycopene. 2006 , 51, 99-164	156
894	Identification of prognostic signatures in breast cancer microarray data using Bayesian techniques. 2006 , 3, 367-81	12
893	Concordance among gene-expression-based predictors for breast cancer. 2006 , 355, 560-9	1071
892	Affymetrix GeneChip system: moving from research to the clinic. 2006 , 6, 145-52	31
891	Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications. 2006 , 5, 1555-67	9
890	Gene expression profiling and clinical outcome in breast cancer. 2006 , 10, 429-43	47
889	Interpreting Microarray Data and Related Applications Using Nonlinear System Identification. 25-53	
888	Integration of gene functional diversity for effective cancer detection. 2006 , 37, 931-938	3
887	Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice. 2006 , 3, 501-16	63
886	Microarray analysis and tumor classification. 2006 , 354, 2463-72	363
885	Cancer biomarkers--an invitation to the table. 2006 , 312, 1165-8	171
884	Gene selection using support vector machines with non-convex penalty. 2006 , 22, 88-95	188
883	Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. 2006 , 66, 5278-86	190
882	Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. 2006 , 59, 611-7	67
881	Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. 2006 , 580, 2935-44	41
880	Gene expression analysis and clinical diagnosis. 2006 , 363, 157-64	26
879	GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. 2006 , 127, 1041-55	479

878	Elevated expression and potential roles of human Sp5, a member of Sp transcription factor family, in human cancers. 2006 , 340, 758-66	33
877	Hhex is a direct repressor of endothelial cell-specific molecule 1 (ESM-1). 2006 , 346, 535-45	18
876	[Elective radiotherapy of the regional lymph node areas in breast cancer]. 2006 , 10, 343-8	0
875	Molecular biology and clinical behavior of oral cancer. 2006 , 18, 483-91	3
874	Expression profiling and individualisation of treatment for ovarian cancer. 2006 , 6, 345-9	14
873	Systematic analysis of the transcriptional switch inducing migration of border cells. 2006 , 10, 497-508	65
872	Identification of HNP3 as a tumour marker in CD4+ and CD4- lymphocytes of patients with cutaneous T-cell lymphoma. 2006 , 42, 249-55	30
871	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. 2006 , 42, 1057-61	7
870	Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site. 2006 , 42, 1897-903	12
869	What clinicians need to know about antioestrogen resistance in breast cancer therapy. 2006 , 42, 2692-705	43
868	Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. 2006 , 42, 2729-37	22
867	Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. 2006 , 42, 3274-86	55
866	Constructing gene expression-based diagnostic rules for understanding individualized etiology of heart failure. 2006 , 1, 33-40	1
865	[Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. 2006 , 54, 209-14	2
864	[DNA microarrays for gene expression profiling of breast cancer: principles and prognostic applications]. 2006 , 54, 49-54	1
863	Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. 2006 , 27, 251-9	165
862	Breast cancer. 2006 , 1, 187-210	2
861	Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy. 2006 , 24, 224-30	

860	Stem cells in prostate and prostate cancer development. 2006 , 24, 131-40	30
859	Genomic profiling in clinical oncology. The predictive value of genomic information in cancer management. 2006 , 119, 56-61	1
858	Data Perturbation Independent Diagnosis and Validation of Breast Cancer Subtypes Using Clustering and Patterns. 2006 , 2, 117693510600200	10
857	Detecting and profiling tissue-selective genes. 2006 , 26, 158-62	43
856	The cell-specific activity of the estrogen receptor alpha may be fine-tuned by phosphorylation-induced structural gymnastics. 2006 , 4, e005	9
855	Familial Breast Cancer, Prevention, Risk Factors and Genetics [Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations. 2006 , 1, 103-106	
854	Section 7: Bioinformatics: Computational Approaches to Analysis of DNA Microarray Data. 2006 , 15, 91-103	4
853	WISP-2 expression in human salivary gland tumors. 2006 , 17, 567	1
852	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. 2006 , 3, e47	476
851	Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. 2006 , 16, 587	1
850	Predictive and Prognostic Markers in Breast Cancer Treatment [Presentations at the 28th San Antonio Breast Cancer Symposium 2005. 2006 , 1, 118-122	
849	Tumor Cell Dissemination and Metastasis in Breast Cancer: Selected Presentations at the 28th San Antonio Breast Cancer Symposium 2005. 2006 , 1, 113-116	1
848	. 2006 ,	25
847	References. 2006 , 401-449	
846	Microarray-based Expression Profiling: From Technological Basics to Diagnostic Perspectives. 728-754	
845	References. 275-380	
844	. 2006 ,	2
843	New Technologies/New Markers/New Challenges. 2006 , 325-331	

842 Profiling cancer expression. **2006**, 6, S22-S22

841 Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. **2006**, 29, 567

16

840 Virology in the 21st century: finding function with functional genomics. **2006**, 1, 47-53

10

839 Gene Expression Profiling with DNA Microarrays. **2006**, 47-61

838 Inference of Genetic Regulatory Networks via Best-Fit Extensions. **2006**, 259-278

837 Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. **2006**, 108, 1677-83

108

836 Molecular and cellular approaches to patient management in oncology. **2006**, 3, 299-310

835 Fast-Lane Evolution in the Tumor Microenvironment. **2006**, 317-329

0

834 Microarray Bioinformatics. **2006**,

833 DNA Chips and Microarrays. **2006**,

832 Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. **2006**, 4, 28-38

10

831 Molecular profiling and personalized predictive pathology: challenge to the academic surgical pathology community. **2006**, 30, 402-4

6

830 Genomic approach to biomarker identification and its recent applications. **2006**, 2, 103-33

31

829 INTEGRATION OF CLINICAL AND MICROARRAY DATA USING BAYESIAN NETWORKS. **2006**, 39, 1174-1179

2

828 Targeting the Survivin Pathway for Rational Cancer Therapy. 427-442

827 Personalized medicine for breast cancer: moving forward and going back. **2006**, 3, 363-370

1

826 Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development. **2006**, 2, 133-143

1

825 The role of disseminated and circulating tumour cells in breast cancer. **2006**, 9,

824	Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. 2006 , 9, 1-3	
823	Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. 2006 , 29, 1581	6
822	Microarray Approaches to Gene Expression Analysis. 2006 , 121-148	1
821	Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. 2006 , 15, 35-42	29
820	Factors that complicate the study of follicular variant of papillary thyroid cancer. 2006 , 12, 250-2	
819	Gene expression determinants of clinical outcome. 2006 , 18, 57-61	9
818	Molecular profiling of breast cancer. 2006 , 18, 59-63	23
817	Genetics and clinical characteristics to predict rheumatoid arthritis: where are we now and what are the future prospects?. 2006 , 1, 79-89	3
816	Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 2006 , 29, 171-7	34
815	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. 2006 , 30, 1097-104	206
814	Microarray expression technology: from start to finish. 2006 , 7, 123-34	24
813	Gene Expression Profiles, Nonlinear System Identification In. 2006 ,	
812	DNA Chip Revolution. 2006 ,	
811	Gene expression profiling of lymph node metastasis by oligomicroarray analysis using laser microdissection in esophageal squamous cell carcinoma. 2006 , 29, 1337	1
810	Learning Kernels from Distance Constraints. 2006 , 2, 441-451	
809	Cross-validated Cox regression on microarray gene expression data. 2006 , 25, 3201-16	125
808	Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. 2006 , 208, 340-9	54
807	Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. 2006 , 209, 307-16	47

806	Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. 2006 , 210, 420-30	61
805	Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. 2006 , 6, 2600-8	39
804	Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. 2006 , 6, 2964-71	69
803	Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. 2006 , 6, 3352-68	124
802	Expanding the protein catalogue in the proteome reference map of human breast cancer cells. 2006 , 6, 2609-25	35
801	Computational exploration of the activated pathways associated with DNA damage response in breast cancer. 2006 , 65, 103-10	2
800	Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. 2006 , 12, 37-47	16
799	The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?. 2006 , 12, 360-2	40
798	Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. 2006 , 12, S196-200	41
797	Microarray analysis of gene expression associated with extrapulmonary dissemination of tuberculosis. 2006 , 11, 557-65	13
796	Quality Management and Stimulation of Technology Transfer in a Research Institute. 2006 , 15, 207-217	3
795	Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. 2006 , 97 Suppl 1, 50-62	78
794	Analysis of gene expression patterns of ovarian cancer cell lines with different metastatic potentials. 2006 , 16, 202-9	17
793	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. 2006 , 16 Suppl 1, 152-65	41
792	Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification. 2006 , 16 Suppl 2, 538-42	13
791	Cytokeratin profiles of male breast cancers. 2006 , 49, 365-70	20
790	Genetic regulators of large-scale transcriptional signatures in cancer. 2006 , 38, 421-30	185
789	A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. 2006 , 38, 1043-8	782

788	Genome-wide analysis of estrogen receptor binding sites. 2006 , 38, 1289-97	1115
787	Where the chips fall. 2006 , 12, 158-9	5
786	Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. 2006 , 6, 117-29	180
785	Common markers of proliferation. 2006 , 6, 99-106	402
784	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. 2006 , 6, 227-39	1005
783	Linking oncogenic pathways with therapeutic opportunities. 2006 , 6, 735-41	139
782	Polycomb silencers control cell fate, development and cancer. 2006 , 6, 846-56	1072
781	Highly parallel genomic assays. 2006 , 7, 632-44	313
780	Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. 2006 , 94, 436-45	34
779	Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. 2006 , 86, 202-11	171
778	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. 2006 , 19, 264-71	806
777	mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. 2006 , 13, 490-502	47
776	Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. 2006 , 13, 706-19	14
775	Cancer transcriptomics: modeling metastasis. 2006 , 14, 1-2	6
774	Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. 2006 , 25, 1413-9	60
773	BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). 2006 , 25, 1391-9	55
772	Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. 2006 , 25, 2328-38	156
771	An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. 2006 , 25, 3994-4008	431

770	Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma. 2006 , 25, 4067-75	14
769	Comparative and integrative functional genomics of HCC. 2006 , 25, 3801-9	96
768	Identification of expressed genes characterizing long-term survival in malignant glioma patients. 2006 , 25, 5994-6002	85
767	Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. 2006 , 25, 6968-74	46
766	Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. 2006 , 25, 5837-45	87
765	Use of genomic signatures in therapeutics development in oncology and other diseases. 2006 , 6, 166-73	118
764	Is tailored therapy feasible in oncology?. 2006 , 57, 79-101	16
763	Clinical trials design and treatment tailoring: general principles applied to breast cancer research. 2006 , 59, 98-105	12
762	Histopathology of BRCA1- and BRCA2-associated breast cancer. 2006 , 59, 27-39	73
761	Evolving clusters in gene-expression data. 2006 , 176, 1898-1927	92
760	Profiling the breast cancer proteome--the new tool of the future?. 2006 , 18, 581-6	4
759	A novel ensemble machine learning for robust microarray data classification. 2006 , 36, 553-73	91
758	Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. 2006 , 65, 646-55	98
757	A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. 2006 , 66, 992-1003	39
756	Artifacts of Markov blanket filtering based on discretized features in small sample size applications. 2006 , 27, 709-714	5
755	Random subspace method for multivariate feature selection. 2006 , 27, 1067-1076	129
754	Stochastic dynamics of metastasis formation. 2006 , 240, 521-30	52
753	PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. 2006 , 30, 1333-9	27

752	DNA biosensor using fluorescence microscopy and impedance spectroscopy. 2006 , 118, 53-59	33
751	Classification of gene-expression data: The manifold-based metric learning way. 2006 , 39, 2450-2463	20
750	Selection bias in working with the top genes in supervised classification of tissue samples. 2006 , 3, 29-41	9
749	Proteomic technology for biomarker profiling in cancer: an update. 2006 , 7, 411-20	37
748	Gene expression profiling of breast cancer. 2006 , 13, 2-7	17
747	Embracing the complexity of genomic data for personalized medicine. 2006 , 16, 559-66	103
746	Genetic prognostic index influences patient outcome for node-positive breast cancer. 2006 , 36, 793-801	22
745	Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. 2006 , 13, 802-8	60
744	A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. 2006 , 13, 1474-84	54
743	A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. 2006 , 6, 803-9	48
742	High-dimensional biology in obstetrics and gynecology: functional genomics in microarray studies. 2006 , 195, 360-3	29
741	BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. 2006 , 5, 135-42	114
740	cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. 2006 , 96, 17-39	49
739	Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses. 2006 , 98, 357-64	10
738	Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. 2006 , 99, 85-90	111
737	Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. 2006 , 25, 69-75	181
736	Improving the prediction of the clinical outcome of breast cancer using evolutionary algorithms. 2006 , 10, 338-345	5
735	Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. 2006 , 7, 67-80	270

734	Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. 2006 , 448, 539-44	19
733	A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles. 2006 , 132, 579-87	9
732	[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis]. 2006 , 27, 319-25	0
731	Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. 2006 , 63, 449-68	190
730	Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. 2006 , 8, 161-72	4
729	Molecular biology of breast cancer. 2006 , 8, 7-14	22
728	Bioinformatics and cancer: an essential alliance. 2006 , 8, 409-15	11
727	Analysis of metastatic-related gene expression in gastric cancer by low-density cDNA microarrays. 2006 , 3, 77-82	
726	Gene expression in breast cancer. 2006 , 7, 123-8	19
725	Genomic signatures in non-small-cell lung cancer: targeting the targeted therapies. 2006 , 8, 252-7	5
724	Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. 2006 , 8, 484-91	8
723	Isolated tumor cells in bone marrow of early-stage breast cancer patients. 2006 , 203, 240-9; quiz A58-9	3
722	X chromosomal abnormalities in basal-like human breast cancer. 2006 , 9, 121-32	649
721	The challenges of gene expression microarrays for the study of human cancer. 2006 , 9, 333-9	80
720	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. 2006 , 10, 145-57	123
719	ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. 2006 , 10, 227-39	136
718	Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. 2006 , 10, 331-42	422
717	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. 2006 , 10, 437-49	466

- 716 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. **2006**, 10, 529-41 998
- 715 Integrated breast cancer genomics. **2006**, 10, 453-4 3
- 714 Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. **2006**, 1765, 25-37 144
- 713 Inflammation and cancer: how hot is the link?. **2006**, 72, 1605-21 1039
- 712 SAGE and related approaches for cancer target identification. **2006**, 11, 110-8 27
- 711 Opening and introductory remarks. **2006**, 15, S1-S3
- 710 Axillary Dissection for Breast Cancer. **2006**, 8, 66-80 4
- 709 Prognostische und prädiktive Faktoren (unter Berücksichtigung von Genexpressionsanalysen). **2010**, 98-108
- 708 Evolutionary q-Gaussian Radial Basis Functions for Improving Prediction Accuracy of Gene Classification Using Feature Selection. **2010**, 327-336
- 707 An Introduction to Toxicogenomics. 1
- 706 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity. 1
- 705 Genomics. 1
- 704 Biomarkers for Detection of Intra-epithelial Neoplasia. **2011**, 151-166
- 703 Preparation of 125. **2010**, 31, 2649-2655
- 702 Hereditary Breast Cancer Syndromes. **2011**, 51-104
- 701 Isolated Limb Perfusion for Melanoma. **2011**, 209-220
- 700 Classifying Data Considering Pairs of Patients in a Relational Space. **2011**, 132-140
- 699 The Comparison of Classification Model with Partial Least Square Based Dimension Reduction. **2011**, 173-180

698 Évolution dans le temps des méthodes diagnostiques et des théories sur la carcinogénèse. **2011**, 3-41

697 Linking Interactome to Disease. **2011**, 406-427

1

696 Systemic Instigation: A Mouse Model to Study Breast Cancer as a Systemic Disease. **2011**, 145-162

695 Analyses génomiques pour la prise en charge du cancer du sein. **2011**, 81-83

694 Cancer, Inflammasomes, and Adjuvanticity. **2011**, 151-163

693 Prediction Analysis for Genomic and Proteomic Data: New Statistical Methods Based on Machine Learning. **2011**, 32, 49-73

692 High-Throughput Genomic and Proteomic Technologies in the Post-genomic Era. **2011**, 1463-1477

691 Experiment Specific Expression Patterns. **2011**, 339-354

690 Kernel-Based Feature Selection with the Hilbert-Schmidt Independence Criterion. **2011**, 140-158

689 The Design of Evolutionary Multiple Classifier System for the Classification of Microarray Data. **2011**, 513-522

688 Introduction on Genome-wide Expression Profiling from Formalin-Fixed Paraffin-Embedded Tissues Using Microarrays. **2011**, 233-237

687 Breast Cancer. **2011**, 169-176

686 Systems Biology, Bioinformatics and Medicine Approaches to Cancer Progression Outcomes. **2011**, 297-307

685 Transcriptomics and Cancer Risk Assessment. 195-205

684 References. **2011**, 553-576

683 Molecular Gene-Signatures and Cancer Clinical Trials. **2012**, 139-155

682 Gene Signatures in CRC and Liver Metastasis. **2012**, 27-33

1

681 The prognostic and predictive value of gene expression signatures in breast cancer. **2011**, 4-12

680 References. 189-196

679 References. **2011**, 217-231

678 Origins of Metastasis-Initiating Cells. **2012**, 229-246

677 Cross Talk Between ER α and Src Signaling and Its Relevance to ER Status and Hormone Responsiveness. **2012**, 61-78

676 Nucleic Acid Techniques. **2012**, 401-442

675 Meta-Analysis of High Throughput Oncology Data. **2012**, 67-95

674 Outils génomiques du choix thérapeutique des cancers du sein. Quelles perspectives à court et moyen terme sur le traitement locorégional. Opinion du radiothérapeute?. **2012**, 435-440

673 Facteurs de décisions en radiothérapie. **2012**, 73-85

672 Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. **2012**, 661-689

671 Fusing Gene Interaction to Improve Disease Discrimination on Classification Analysis. **2012**, 1, 1000102 1

670 A Method for the Detection of Meaningful and Reproducible Group Signatures from Gene Expression Profiles. **2012**, 387-401

669 Comparison of Data-Merging Methods with SVM Attribute Selection and Classification in Breast Cancer Gene Expression. **2012**, 498-507 4

668 Tumor Markers. **2012**, 617-667 1

667 Molecular Classification of Breast Carcinoma. **2012**, 365-379

666 Pattern Discovery from Biological Data. **2012**, 724-768

665 Random Walking on Functional Interaction Networks to Rank Genes Involved in Cancer. **2012**, 66-75 2

664 Analysis of Array Data and Clinical Validation of Array-Based Assays. **2012**, 171-210

663 Molecular biology as applied to head and neck oncology. **2012**, 24-37

662 Prognostic Markers in Breast Cancer. **2013**, 25-42

661 Novel Biclustering Methods for Re-ordering Data Matrices. **2013**, 1-39

660 Mathematical Models of Supervised Learning and Application to Medical Diagnosis. **2013**, 67-81

659 Molecular Markers of Prostate Cancer Outcome. **2013**, 189-247

658 Role of IL-17 and IL-17 Family Cytokines on Tumor Development. **2013**, 219-230

657 Systems Biology Approaches in Breast Cancer Studies. **2013**, 329-340

o

656 Molecular Classification. **2013**, 21-34

655 Molecular investigation of breast cancer. **2013**, 286-304

654 Pharmacogenomics in Acute Myeloid Leukemia. **2013**, 237-248

1

653 MicroRNA Expression in Breast Cancer Revealed by Deep Sequencing Technology. **2013**, 233-261

652 Gene Selection for SRBCTs Subtype Classification Using Fuzzy Neural Network. **2013**, 1, 134-137

1

651 Mechanisms of Metastasis. **2013**, 435-458

1

650 Role of Stroma in Disease Progression. **2013**, 129-147

649 Next-Generation Sequencing for Cancer Genomics. **2013**, 55-74

1

648 Is Tumor Dormancy Clinically Relevant?. **2013**, 7-21

647 Histological risk factors, prognostic indicators and staging. **2013**, 236-249

646 Innovative Technologies in the Molecular Characterization of Pancreatic Cancer. **2013**, 209-228

645 An Incremental Linear Programming Based Tool for Analyzing Gene Expression Data. **2013**, 48-64

644 Mutational Genomics for Cancer Pathway Discovery. **2013**, 35-46

643 Définition biologique de l'agressivité tumorale : les signatures biologiques peuvent-elles être utilisées en pratique clinique ?. **2013**, 72-78

642 Signaling Networks of Activated Oncogenic and Altered Tumor Suppressor Genes in Head and Neck Cancer. **2013**, Suppl 7, 4

4

641 Introduction. **2013**, 3-10

640 Facing a Shift in Paradigm at the Bedside?. **2013**, 04, 35-40

639 - Spliceomics: The OMICS of RNA Splicing. **2013**, 224-247

638 The effect of biology in the treatment of small breast tumors. **2013**, 25-31

637 Ductal carcinoma in situ: how should we treat it?. **2013**, 2, 245-256

636 Gene Expression Profiling in Melanoma. **2014**, 529-545

635 MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients. **2013**, 387-415

634 Reproductive System. **2014**, 89-136

633 Metastasis. **2014**, 211-272

632 Systemic Therapy. **2014**, 381-420

631 Diagnostic and Therapeutic Mesenchymal Stem Cells for Breast Cancer Treatment. 145-158

630 Molecular Pathology and Diagnostics of Breast Cancer. **2014**, 57-73

629 Molecular Pathology and Diagnostics of Pancreatic Endocrine Neoplasms. **2014**, 423-448

628 miRNAs as Cancer Biomarkers. **2014**, 97-124

627 Cancer Pathology. **2014**, 21-34

- 626 Integration of Clinico-Pathological and microRNA Data for Intelligent Breast Cancer Relapse Prediction Systems. **2014**, 178-193 o
- 625 Microarray-Based Investigations in Cancer. **2014**, 87-106
- 624 The role of adjuvant systemic therapy in patients with operable breast cancer. **2014**, 199-218
- 623 Metabolomics in Breast Cancer. **2014**, 211-224
- 622 Encyclopedia of Machine Learning and Data Mining. **2014**, 1-24
- 621 Omics Technologies Applied in Breast Cancer Research. **2014**, 3-15
- 620 Molekularbiologie und Genetik. **2014**, 101-115
- 619 Epirubicin/Cyclophosphamide followed by Docetaxel as Primary Systemic Therapy in Breast Cancer. **2014**, 22, 19-23
- 618 A Biclustering-Based Classification Framework for Microarray Analysis. **2014**, 429-440
- 617 CHAPTER 7:MS1 Label-free Quantification Using Ion Intensity Chromatograms in Skyline (Research and Clinical Applications). **2014**, 154-174 o
- 616 Molecular Testing in Breast Cancer. **2014**, 169-188
- 615 Mining Diversified Shared Decision Tree Sets for Discovering Cross Domain Similarities. **2014**, 534-547
- 614 Superresolution MUSIC Based on Markov-Pastur Limit Distribution Reduces Uncertainty and Improves DNA Gene Expression-Based Microarray Classification. **2014**, 194-209
- 613 Cancer After Metastasis: The Second Transformation. **2014**, 279-304
- 612 A Genomic Analysis of Cellular Responses and Adaptions to Extracellular Acidosis. **2014**, 135-157
- 611 Expression Tests in Actual Clinical Practice: How Medically Useful is the Transcriptome?. **2014**, 327-340
- 610 OMICS for Tumor Biomarker Research. **2014**, 1-22
- 609 Bioinformatics and Nanotechnologies: Nanomedicine. **2014**, 517-532

608 Omics of Hereditary Breast Cancer. **2014**, 17-40

607 Searching for Patterns in Imbalanced Data. **2014**, 159-166

606 A Stable Instance Based Filter for Feature Selection in Small Sample Size Data Sets. **2014**, 334-344

605 GENETICS FOR DIAGNOSTICS IN PREVENTIVE MEDICINE. **2014**, 13, 75-80

604 Early Breast Cancers. **2015**, 61-112

603 Genomic Applications in Breast Carcinoma. **2015**, 359-382

602 Neural networks and Fuzzy clustering methods for assessing the efficacy of microarray based intrinsic gene signatures in breast cancer classification and the character and relations of identified subtypes. **2015**, 1260, 285-317

601 Analysis of AmpliSeq RNA-Sequencing Enrichment Panels. **2015**, 495-500

600 Gene Selection Based On an Improved Iterative Feature Elimination Random Survival Forest. **2015**, 2015, 124-129

599 Pharmacogenetics and Antineoplastic Therapies. **2015**, 275-305

598 Gene Fusions in Prostate Cancer. **2015**, 381-401

597 Systems Biology, Information Technology, and Cancer Research. **2015**, 147-211

596 Current and Evolving Technologies. **2015**, 11-34

595 Kinesin-8 Members and Their Potential as Biomarker or Therapeutic Target. **2015**, 171-191

594 Cell-Specific Aptamers for Disease Profiling and Cell Sorting. **2015**, 197-213

593 Feature Selection and Analysis of Gene Expression Data Using Low-Dimensional Linear Programming. **2015**, 235-264

592 Specimens for Molecular Testing in Breast Cancer. **2015**, 317-327

591 Breast cancer and neutropenic sepsis. **2015**, 1-10

590 Tumors of the breast. 426-446

589 From Gene Expression to Disease Phenotypes: Network-Based Approaches to Study Complex Human Diseases. **2016**, 115-140

588 Expression Profiling, MammaPrint Assay. **2016**, 482-483

587 The prognostic potential of alternative transcript isoforms across human tumors.

586 Gene Expression Analysis: Current Methods. **2016**, 107-136

o

585 Gene Arrays, Prognosis, and Therapeutic Interventions. **2016**, 207-227

584 Genomic Markers in ER-Negative Breast Cancer. **2016**, 283-298

583 Personalisation of Radiotherapy for Breast Cancer. **2016**, 131-149

582 Construction of 3-Plex Barcodes for Differential Gene Expression Analysis with Pyrosequencing. **2016**, 217-230

581 Breast Cancer Molecular Testing for Prognosis and Prediction. **2016**, 195-202

580 Information Extraction from Microarray Data. **2016**, 1180-1211

1

579 Molecular Diagnostics: Translation from Discovery to Clinical Practice. **2016**, 1-26

578 Breast Cancer. **2016**, 433-446

577 How to Build Up Adequate Prognostic Markers in the Molecular Biology Context of Breast Cancer. **2016**, 149-181

576 Breast Cancer Molecular Subtypes Among Moroccan Women. **2016**, 3, 47-54

575 Prognostic and Predictive Gene Expression Signatures in Breast Cancer. **2016**, 269-281

574 A nonparametric Bayesian technique for high-dimensional regression. **2016**, 10,

o

573 Comparative Gene Expression Analysis of Breast Cancer-Related Genes by Multiplex Pyrosequencing Coupled with Sequence Barcodes. **2016**, 315-325

o

572 Adjuvant Systemic Chemotherapy for HER2-Negative Disease. **2016**, 131-187

571 Gene Expression Analysis: Applications. **2016**, 137-149

570 Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes. **2016**, 7, 21686-98 2

569 Mining Emerging Patterns for Activity Recognition. **2016**, 341-352

568 A comparative study of filter methods based on information entropy. **2016**, 40, 437-446 2

567 Prognostic Value of SUVmax of ^{18}F -FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis. **2017**, 07, 112-123

566 Encyclopedia of Machine Learning and Data Mining. **2017**, 143-163

565 (L₁)-regularization Model Enriched with Biological Knowledge. **2017**, 579-590 2

564 Bootstrap-Based LASSO-Type Selection to Build Generalized Additive Partially Linear Models for High-Dimensional Data. **2017**, 405-424

563 Molecular Classification of Breast Cancer. **2017**, 1-22

562 Big Data and DynamicsThe Mathematical Toolkit Towards Personalized Medicine. **2017**, 338-369

561 Survival-Expression Map and Essential Forms of Survival-Expression Relations for Genes. **2017**, 641-649 0

560 Prediction of Molecular Mechanisms of Breast Cancer Metastasis.

559 Systems-level Analysis of 32 TCGA Cancers Reveals Disease-dependent tRNA Fragmentation Patterns and Very Selective Associations with Messenger RNAs and Repeat Elements.

558 Reparameterization of PAM50 expression identifies novel breast tumor dimensions and leads to discovery of a breast cancer susceptibility locus at 12q15.

557 A Nasal Brush-based Classifier of Asthma Identified by Machine Learning Analysis of Nasal RNA Sequence Data.

556 Change of Title: Microarrays Becomes High-Throughput. **2017**, 6, 1

555 Change of Title: Microarrays Becomes High-Throughput. **2017**, 6, 1 0

- 554 A Biomaterial Screening Approach Reveals Microenvironmental Mechanisms of Drug Resistance. 1
- 553 GAC: Gene Associations with Clinical, a web based application. **2017**, 6, 1039 1
- 552 GAC: Gene Associations with Clinical, a web based application. 6, 1039
- 551 Identification of potential blood-derived extracellular vesicles biomarkers to diagnose and predict distant metastases in ER+ breast cancer patients. 3
- 550 PREVALENCE OF MOLECULAR SUBTYPES OF CARCINOMA OF BREAST- A STUDY FROM NORTH INDIA. **2017**, 6, 6204-6207 1
- 549 CKS protein overexpression renders tumors susceptible to a chemotherapeutic strategy that protects normal tissues. **2017**, 8, 114911-114923
- 548 Competition and niche construction in a model of cancer metastasis.
- 547 Microarray Bioinformatics. 1-7
- 546 The Spectrum of Risk Lesions in Breast Pathology: Risk Factors or Cancer Precursors?. **2018**, 1-19
- 545 Encyclopedia of Signaling Molecules. **2018**, 4752-4756
- 544 Bi-objective Genetic Algorithm with Rough Set Theory for Important Gene Selection in Disease Diagnosis. **2018**, 279-298
- 543 A Visual Analytics Technique for Exploring Gene Expression in the Developing Mouse Embryo. **2018**, 137-151 0
- 542 TuBA: Tunable Biclustering Algorithm Reveals Clinically Relevant Tumor Transcriptional Profiles in Breast Cancer.
- 541 ANNC: AUC-Based Feature Selection by Maximizing Nearest Neighbor Complementarity. **2018**, 772-785
- 540 GAC: Gene Associations with Clinical, a web based application. 6, 1039
- 539 A data-driven interactome of synergistic genes improves network based cancer outcome prediction.
- 538 The evaluation of gait problems and related factors in patients with Parkinson's disease. **2018**, 2,
- 537 A Computational Framework for Personalised Modelling. Applications in Bioinformatics. **2019**, 563-591

- 536 Comprehensive Genomic Characterization of Breast Tumors with BRCA1 and BRCA2 Mutations.
- 535 Network-aware mutation clustering of cancer.
- 534 Prognostic and Predictive Factors. **2019**, 171-186
- 533 A cross-cancer metastasis signature in the microRNA-mRNA axis of paired tissue samples.
- 532 EpiSmokEr: A robust classifier to determine smoking status from DNA methylation data.
- 531 Case Studies: Molecular Pathology Perspective and Impact on Oncologic Patients Management. **2019**, 191-216
- 530 Frontiers in Precision Medicine IV: Artificial Intelligence, Assembling Large Cohorts, and the Population Data Revolution.
- 529 Research, Clinical Trials and Evidence-Based Medicine for Older Patients with Breast Cancer. **2019**, 251-261
- 528 Clinical Application of Molecular Features in Therapeutic Selection and Drug Development. **2019**, 137-166 1
- 527 The Anaphase Promoting Complex/Cyclosome (APC/C): A Versatile E3 Ubiquitin Ligase. **2019**, 93, 539-623 1
- 526 Adjuvant Systemic Chemotherapy for HER2-Negative Disease. **2019**, 129-171
- 525 Gene Arrays, Prognosis, and Therapeutic Interventions. **2019**, 173-189
- 524 Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. **2019**, 237-268
- 523 Prognostic and Predictive Factors. **2019**, 163-172
- 522 APTER: Aggregated Prognosis Through Exponential Re-weighting. **2019**, 425-436
- 521 Role of Heat Shock Protein 90 in Mammary Tumorigenesis. **2019**, 103-124
- 520 Testing for dependence on tree structures. o
- 519 E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration.

518 Ginecolog  endocrina: m todos de determinaci n, exploraci n din mica y molecular. **2019**, 55, 1-13

517 Inferring Causal Associations between Genes and Disease via the Mapping of Expression Quantitative Trait Loci. **2019**, 697-38

1

516 Yeast Bax Inhibitor (Bxi1p/Ybh3p) is a Calcium Channel in *E. coli*.

515 Early-life adversity is associated with differential gene expression in response to acute psychological stress: preliminary findings.

514 Evaluating Ensemble Learning Impact on Gene Selection for Automated Cancer Diagnosis. **2020**, 183-186

1

513 Maximizing the Reusability of Public Gene Expression Data by Predicting Missing Metadata.

512 Determining Missing Key Elements in Oncology Information System to Improve Patient Experience and Clinical Care. **2020**, 567-586

511 Personalized single-cell networks: a framework to predict the response of any gene to any drug for any patient.

2

510 Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. **2019**, 18, 6690-6696

3

509 Molecular Profiles of Breast Cancer in Hispanic/Latina. **2020**, 103-109

0

508 Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor.

1

507 Metformin Had Potential to Increase Endocan Levels in STZ-Induced Diabetic Mice. **2020**, 26, 133-141

0

506 Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer. **2020**, 20, 126

2

505 A Survey of Modern Gene Expression Based Techniques for Cancer Detection and Diagnosis. **2021**, 35-50

1

504 Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1.

503 Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy. **2021**, 23, 412-419

0

502 Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. **2021**, 21, 1165

0

501 Molecular Basis of Breast Cancer. **2022**, 3-15

- 500 Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients. **2020**, 15, e0244693 1
- 499 Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer. **2021**, 62, 1592-1600 0
- 498 CCDC170 affects breast cancer apoptosis through IRE1 pathway. **2020**, 13, 1332-1356 3
- 497 In-silico analysis of differentially expressed genes and their regulating microRNA involved in lymph node metastasis in invasive breast carcinoma.
- 496 Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. **2020**, 10, 21930 2
- 495 Summary Visualisations of Gene Ontology Terms with GO-Figure!. 0
- 494 A novel gene expression test method of minimizing breast cancer risk in reduced cost and time by improving SVM-RFE gene selection method combined with LASSO. **2020**, 18, 139-153 1
- 493 Biomarkers in drug development. **2022**, 323-342 1
- 492 CHAPTER 5:Big Data and Its Emerging Role in Precision Medicine and Therapeutic Response. **2020**, 88-116
- 491 A Brief Overview on Intelligent Computing-Based Biological Data and Image Analysis. **2020**, 65-89
- 490 Carbonic Anhydrase Isozymes as Diagnostic Biomarkers and Therapeutic Targets. **2021**, 13-36
- 489 The Explanation Game: A Formal Framework for Interpretable Machine Learning. **2021**, 109-143
- 488 The Explanation Game: A Formal Framework for Interpretable Machine Learning. **2021**, 185-219 2
- 487 Biochips. **2021**, 185-224
- 486 Envisioning the Application of Systems Biology in Cancer Immunology. **2020**, 599-624
- 485 The role of interactomic interactions in tamoxifen-resistant breast cancer: new approaches to searching for the mechanisms of pathogenesis. **2020**, 9, 80 0
- 484 A Data Integration Approach for Detecting Biomarkers of Breast Cancer Survivability. **2020**, 49-60
- 483 Linear Classifiers with the L1 Margin from a Small Number of High-Dimensional Vectors. **2020**, 79-89 1

- 482 Correlation between MR Image-Based Radiomics Features and Risk Scores Associated with Gene Expression Profiles in Breast Cancer. **2020**, 81, 632
- 481 Systems Biology and Biomarkers in Necrotizing Soft Tissue Infections. **2020**, 1294, 167-186 1
- 480 Decision Tree Model Based Gene Selection and Classification for Breast Cancer Risk Prediction. **2020**, 165-177
- 479 A novel single-cell based method for breast cancer prognosis.
- 478 Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer. **2021**, 1 0
- 477 Band-based similarity indices for gene expression classification and clustering. **2021**, 11, 21609
- 476 Nomogram for the personalisation of radiotherapy treatments in breast cancer patients. **2021**, 60, 255-262
- 475 Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis. **2021**, 134, 2692-2699 0
- 474 Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. **2021**, 27, 1175
- 473 PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT.
- 472 Linking Interactome to Disease. 151-172
- 471 Machine Learning for Clinical Data Processing. 193-215 0
- 470 Molecular markers in breast cancer: current practice and future possibilities. **2005**, 563, 35-41 0
- 469 Cancer Diagnosis. 427-447
- 468 Dynamic Nature of Tumour-Host Interactions Within the Tumor Microenvironment. **2005**, 177-187
- 467 Gene Expression Signatures of TGF- β /Smad-Induced Responses. **2006**, 335-360
- 466 Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. **2006**, 205-220
- 465 Dawn of a new era in molecular cancer therapeutics. **2005**, 63, 1-17 1

464 Heat Shock Proteins in the Progression of Cancer. **2007**, 422-450

463 Comparative Genomics of Tissue Specific Gene Expression. **2006**, 393-408

462 Mining Interesting Clinico-Genomic Associations: The HealthObs Approach. **2007**, 137-145

2

461 Systematic Validation of Breast Cancer Biomarkers Using Tissue Microarrays: From Construction to Image Analysis. **2008**, 235-250

460 Lymph Node-Negative Breast Carcinoma: Assessment of HER-2/neu Gene Status as Prognostic Value. **2008**, 569-581

459 Barrett's Esophagus. **2005**, 325-342

458 Potential Use of Transgenic Mice in Chemoprevention Studies. **2005**, 47-55

457 Molecular Biology Applications in Cardiovascular Medicine. **2005**, 11-43

456 Molecular Profiling in Breast Cancer. **2006**, 559-576

455 Considerations When Using Array Technologies for Male Factor Assessment. **2007**, 37-54

454 Expression Profiling of Prostate Cancer Progression. **2007**, 247-267

453 Microarray-based Gene Expression Analysis of Endocrine Systems: Principles of Experimental Design and Interpretation. **2008**, 3-22

452 From Tissue Samples to Tumor Markers. **2007**, 17-28

451 Targeted Therapy For Breast Cancer. **2008**, 309-342

450 DNA and Tissue Microarrays. **2007**, 98-108

449 Intégration des nouvelles technologies de biologie dans le choix de la stratégie thérapeutique 2007. **2007**, 167-184

448 Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer. **2006**, 327-348

447 Tailored Therapy for Breast Cancer in Very Young Women. **2006**, 349-374

- 446 Genomic and Molecular Classification of Breast Cancer. **2006**, 595-621
- 445 Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. **2006**, 671-704
- 444 Mechanisms of Resistance to Hormone Therapy. **2006**, 805-821
- 443 Clinical Trials in the Era of Treatment Tailoring. **2006**, 1007-1020
- 442 Genetische Veränderungen des sporadischen Mammakarzinoms. **2006**, 119-125
- 441 Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom. **2006**, 183-198
- 440 Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. **2008**, 15-32
- 439 Choices for surgery. **2007**, 175, 163-78
- 438 Resistance-associated signatures in breast cancer. **2007**, 176, 37-50
- 437 Boosting Threshold Classifiers for High Dimensional Data in Functional Genomics. **2008**, 147-156 0
- 436 A Tree Index to Support Clustering Based Exploratory Data Analysis. **2008**, 1-15 1
- 435 A Novel Relative Space Based Gene Feature Extraction and Cancer Recognition. **2007**, 712-719 1
- 434 The Synergy of Two Ovarian Hormone-induced Enzymes in Human Mammary Carcinogenesis. **2008**, 99-109
- 433 Informative Gene Selection and Tumor Classification by Null Space LDA for Microarray Data. **2007**, 435-446 5
- 432 Cancer Identification Based on DNA Microarray Data. **2007**, 153-161 2
- 431 Network-Based Inference of Cancer Progression from Microarray Data. **2008**, 268-279 1
- 430 Analysis of Array Data and Clinical Validation of Array-Based Assays. **2012**, 171-210 0
- 429 Molekularbiologie und Genetik. **2014**, 101-115 0

- 428 Accurate Prediction of Breast Cancer Survival through Coherent Voting Networks with Gene Expression Profiling.
- 427 Effects of underlying gene-regulation network structure on prediction accuracy in high-dimensional regression.
- 426 Multi-Objective Approach for Identifying Cancer Subnetwork Markers.
- 425 NeTFactor, a framework for identifying transcriptional regulators of gene expression-based biomarkers. **2020**, 1
- 424 Maximizing the reusability of gene expression data by predicting missing metadata. **2020**, 16, e1007450 0
- 423 Kinase-substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer. **2020**, 18, 525-538
- 422 Clinical proteomics: present and future prospects. **2006**, 27, 99-116 50
- 421 Mechanisms of oncogenic cooperation in cancer initiation and metastasis. **2006**, 79, 95-103 27
- 420 Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. **2007**, 5, 463-470 49
- 419 Methods in molecular cardiology: microarray technology. **2003**, 11, 213-220
- 418 Statistical issues and analyses of in vivo and in vitro genomic data in order to identify clinically relevant profiles. **2007**, 3, 231-43 1
- 417 Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. **2009**, 16, 56-8 4
- 416 Clinical arrays of laboratory measures, or "clinarrays", built from an electronic health record enable disease subtyping by severity. **2007**, 115-9 8
- 415 Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties. **2008**, 32, 797-807 27
- 414 Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns. **2007**, 2, 243-74 9
- 413 Feature selection for predicting tumor metastases in microarray experiments using paired design. **2007**, 3, 213-8 12
- 412 Combining clinical and genomic covariates via Cov-TGDR. **2007**, 3, 371-8 4
- 411 A practical multifaceted approach to selecting differentially expressed genes. **2008**, 3, 203-12

410	State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments. 2005 , 3, Doc08	4
409	Multianalyte tests for the early detection of cancer: speedbumps and barriers. 2007 , 2, 261-7	
408	Trastuzumab in the management of early and advanced stage breast cancer. 2007 , 1, 19-31	31
407	Master regulators used as breast cancer metastasis classifier. 2009 , 504-15	41
406	Technology as a force for improved diagnosis and treatment of breast disease. 2010 , 53, 268-77	18
405	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. 2010 , 4, 35-41	389
404	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
403	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. 2011 , 1, 787-805	22
402	The role of survivin in diagnosis, prognosis and treatment of breast cancer. 2010 , 2, 100-10	47
401	Progress in myeloma stem cells. 2011 , 1, 135-45	15
400	A Partitioning Based Adaptive Method for Robust Removal of Irrelevant Features from High-dimensional Biomedical Datasets. 2012 , 2012, 52-61	2
399	A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to bone. 2012 , 123, 135-50; discussion 150-1	3
398	[Molecular classification of breast cancer in Morocco]. 2012 , 13, 91	6
397	Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study. 2013 , 77, 142-9	5
396	Classification of breast carcinomas according to gene expression profiles. 2013 , 6, 14-7	7
395	Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer. 2013 , 3, 446-64	11
394	Identifying gene networks underlying the neurobiology of ethanol and alcoholism. 2012 , 34, 306-17	9
393	Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model. 2012 , 4, 31-40	33

392	Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. 2013 , 6, 165-73	3
391	Differential expression of DNA repair genes in Hispanic women with breast cancer. 2013 , 1, 54	10
390	T-ReCS: stable selection of dynamically formed groups of features with application to prediction of clinical outcomes. 2015 , 431-42	8
389	Selective model averaging with bayesian rule learning for predictive biomedicine. 2014 , 2014, 17-22	2
388	Bax inhibitor-1 is overexpressed in non-small cell lung cancer and promotes its progression and metastasis. 2015 , 8, 1411-8	11
387	Application of Bayesian logistic regression to mining biomedical data. 2014 , 2014, 266-73	2
386	Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation. 2015 , 5, 1730-40	18
385	Breast cancer intrinsic subtype classification, clinical use and future trends. 2015 , 5, 2929-43	296
384	Breed- and age-related differences in canine mammary tumors. 2016 , 80, 146-55	4
383	Prognostic signatures of breast cancer: Perou's molecular subtypes and Schmidt's metagenes. 2012 , 11, 204-7	4
382	RAS pathway biomarkers for breast cancer prognosis. 2016 , 40, 18-23	6
381	Systematic Analysis of Free-Text Family History in Electronic Health Record. 2017 , 2017, 104-113	12
380	Improving the efficiency of biomarker identification using biological knowledge. 2009 , 427-38	7
379	Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. 2017 , 146, 563-571	3
378	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. 2016 , 7, 666-671	
377	Comparative study of gastric cancer and chronic gastritis via network analysis. 2018 , 11, 343-351	11
376	Egr-1 suppresses breast cancer cells proliferation by arresting cell cycle progression via down-regulating CyclinDs. 2017 , 10, 10212-10222	5
375	Ribonuclease H2 Subunit A impacts invasiveness and chemoresistance resulting in poor survivability of breast cancer in ER dependent manner. 2020 , 12, 2281-2294	3

- 374 Frequent Subgraph Mining of Functional Interaction Patterns Across Multiple Cancers. **2021**, 26, 261-272
- 373 An immune-related signature that to improve prognosis prediction of breast cancer. **2021**, 11, 1267-1285 4
- 372 Empirical Comparison of Continuous and Discrete-time Representations for Survival Prediction. **2021**, 146, 118-131
- 371 MELK expression in breast cancer is associated with infiltration of immune cell and pathological complete response (pCR) after neoadjuvant chemotherapy. **2021**, 11, 4421-4437 1
- 370 A Text-Based Computational Framework for Patient-Specific Modeling for Classification of Cancers.
- 369 Transcription factor NF- κ B, interleukin-1 β and interleukin-8 expression and its association with tobacco smoking and severity in chronic obstructive pulmonary disease. **2022**, 26, 101453
- 368 A combinatory algorithm for identifying genes in childhood acute lymphoblastic leukemia. **2022**, 26, 101433
- 367 A novel filter based feature selection approach for microarray dataset. **2021**,
- 366 Prognostic and Genomic Analysis of Proteasome 20S Subunit Alpha (PSMA) Family Members in Breast Cancer.. **2021**, 11, 1 1
- 365 Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy. **2021**, 16, 223 1
- 364 Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. **2021**, 5, 0
- 363 Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. **2021**, 26, 300574 2
- 362 Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors. **2021**, 12, 6692 3
- 361 MammaPrint and Blueprint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. **2021**, 1 1
- 360 Germline breast cancer susceptibility genes, tumor characteristics, and survival. **2021**, 13, 185 0
- 359 Predictive Signatures for Lung Adenocarcinoma Prognostic Trajectory by Multiomics Data Integration and Ensemble Learning. **2021**, 9-23
- 358 Recurrencia y características clínicas patológicas en los grupos de riesgo establecidos por Oncotype Dx, original y TAILORx, en cáncer de mama temprano. **2021**, 66, 263-272
- 357 Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells.. **2021**, 1328, 21-35 0

356	A Hybrid Mutual Information-LASSO-Genetic Algorithm Selection Approach for Classifying Breast Cancer. 2022 , 547-560	1
355	Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.. 2021 , 11, 780118	0
354	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making.. 2021 , 11,	1
353	Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.. 2022 , 1	
352	Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.. 2022 , 12, 1317	0
351	Robust multi-class feature selection via l2,0-norm regularization minimization. 2022 , 26, 57-73	0
350	Breast Cancer Survival Prediction using Machine Learning and Gene Expression Profiles.	
349	ABI1-based expression signature predicts breast cancer metastasis and survival.. 2021 ,	0
348	An 11-Gene Signature Based on Treatment Responsiveness Predicts Radiation Therapy Survival Benefit Among Breast Cancer Patients.. 2021 , 11, 816053	0
347	Bioinformatics Analysis of the Potentially Functional circRNA-miRNA-mRNA Network in Breast Cancer.	
346	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. 2022 , JCO2102019	4
345	SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling.. 2022 , 79, 59	2
344	X Curso internacional de avances en Oncolog�a: investigaci�n y nuevos f�rmacos. 2003 , 5, 98-110	
343	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. 2022 , 1	0
342	Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.. 2022 , 2022, 1322788	1
341	A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.. 2022 , 12, 2211	
340	Transcriptome analysis method based on differential distribution evaluation.. 2022 ,	0
339	Differential gene expression and network analysis in head and neck squamous cell carcinoma.. 2022 , 1	

338	Theranostic Interpolation of Genomic Instability in Breast Cancer.. 2022 , 23,	0
337	Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.. 2022 , 14,	1
336	Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance.. 2022 , 1	1
335	TP53 knockout in MCF7 breast cancer cells induces sensitivity to fluoropyrimidine drugs..	
334	KRas-transformed epithelia cells invade and partially dedifferentiate by basal cell extrusion. 2021 , 12, 7180	5
333	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2021 ,	50.4 15
332	A metastasis-on-a-chip approach to explore the sympathetic modulation of breast cancer bone metastasis.. 2022 , 13, 100219	0
331	Artificial Intelligence in Blood Transcriptomics. 2022 , 1109-1123	
330	Prognostic Values and Underlying Regulatory Network of Cohesin Subunits in Esophageal Carcinoma.. 2022 , 13, 1588-1602	0
329	Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer.. 2022 , 14, 761-773	
328	Identification of Immune Markers in Dilated Cardiomyopathies with Heart Failure by Integrated Weighted Gene Coexpression Network Analysis.. 2022 , 13,	0
327	Early Changes in Quantitative Ultrasound Imaging Parameters during Neoadjuvant Chemotherapy to Predict Recurrence in Patients with Locally Advanced Breast Cancer.. 2022 , 14,	0
326	A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres.. 2022 , 14, 25	0
325	Multimomics Topic Modeling for Breast Cancer Classification.. 2022 , 14,	0
324	A Combined Feature Screening Approach of Random Forest and Filter-based Methods for Ultra-high Dimensional Data. 2022 , 17,	0
323	The extended concurrent genes signature for disease-free survival in breast cancer.. 2022 ,	0
322	The Role of the 21-Gene Recurrence Score Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience.. 2022 , 29, 2008-2020	0
321	Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.. 2022 , 14,	2

320	Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer.. 2022 , 14,	O
319	A text-based computational framework for patient -specific modeling for classification of cancers.. 2022 , 25, 103944	1
318	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.. 2022 , 14,	1
317	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.	O
316	Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.. 2022 ,	1
315	Visualizing Cytokeratin-14 Levels in Basal-Like Breast Cancer via ImmunoSPECT Imaging.. 2022 ,	O
314	NetRank Recovers Known Cancer Hallmark Genes as Universal Biomarker Signature for Cancer Outcome Prediction. 2022 , 2,	
313	ExhauFS: exhaustive search-based feature selection for classification and survival regression.. 2022 , 10, e13200	1
312	Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer.. 2022 , 18, e1009495	
311	Supporting shared decision making about personalised surveillance after breast cancer: the development of a patient decision aid integrating personalised recurrence risk calculations (Preprint).	
310	Optimized feature selection method using particle swarm intelligence with ensemble learning for cancer classification based on microarray datasets. 1	1
309	PLUS: Predicting cancer metastasis potential based on positive and unlabeled learning.. 2022 , 18, e1009956	1
308	Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention.. 2022 , 10,	1
307	Transcriptome-wide association and prediction for carotenoids and tocochromanols in fresh sweet corn kernels.. 2022 , e20197	O
306	The ability to classify patients based on gene-expression data varies by algorithm and performance metric.. 2022 , 18, e1009926	O
305	Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer.. 2022 , 12,	O
304	Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.. 2022 , 1	
303	NRF2 drives an oxidative stress response predictive of breast cancer.. 2022 ,	O

- 302 A new feature selection method based on feature distinguishing ability and network influence.. **2022**, 128, 104048 4
- 301 Transcriptome profiling of curcumin-treated T47D human breast cancer cells by a system-based approach. **2022**, 27, 101556 0
- 300 End-to-end computational approach to the design of RNA biosensors for detecting miRNA biomarkers of cervical cancer.. **2022**, 7, 802-814 0
- 299 Outcome-guided sparse K-means for disease subtype discovery via integrating phenotypic data with high-dimensional transcriptomic data. **2022**, 71, 352-375
- 298 A probabilistic model for pathway-guided gene set selection. **2021**,
- 297 geneExpressionFromGEO: An R Package to Facilitate Data Reading from Gene Expression Omnibus (GEO).. **2022**, 2401, 187-194 1
- 296 The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.. **2021**, 7, 156 1
- 295 Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer.. **2021**, 21, 708 2
- 294 A robust drug representation learning model for eliminating cell specificity in gene expression profile and its application. **2021**,
- 293 Multi-omics Topic Modeling for Breast Cancer Classification.
- 292 High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.. **2021**, 0
- 291 Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound.. **2021**, 12, 2437-2448 1
- 290 Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. **2021**, 11, e053674 4
- 289 Predicting Breast Cancer Gene Expression Signature by Applying Deep Convolutional Neural Networks From Unannotated Pathological Images.. **2021**, 11, 769447 0
- 288 Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. **2021**, 1-19 2
- 287 Integration of DNA Microarray with Clinical and Genomic Data.. **2022**, 2401, 239-248
- 286 A Novel Data Analytics-derived Metric (Nearest Cluster Distance) Is Easily Implemented in Routine Practice and Correctly Identifies Breast Cancer Cases for Quality Review.. **2022**, 13, 100005
- 285 TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource.

- 284 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.. **2022**, 9, 783494 0
- 283 Using Technology to Personalize Middle School Math Instruction: Evidence From a Blended Learning Program in Five Public Schools. **2022**, 7, 0
- 282 Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.. **2022**, 0
- 281 A comprehensive study of mRNA and long noncoding RNAs in Indian Breast cancer patients using transcriptomics approach. 0
- 280 Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.. **2022**, 0
- 279 Weighted p-norm distance t kernel SVM classification algorithm based on improved polarization.. **2022**, 12, 6197 1
- 278 HSVNN: an efficient medical data classification using dimensionality reduction combined with hybrid support vector neural network. 1 0
- 277 Cmp signaling network unveils novel biomarkers for triple negative breast cancer in African American women.. **2022**, 3
- 276 Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and Blueprint to guide preoperative systemic treatment decisions.. **2022**, 167, 92-102 0
- 275 Systems biology of cancer progression. 1-6
- 274 Data_Sheet_1.pdf. **2020**,
- 273 Data_Sheet_1.PDF. **2019**,
- 272 Table_1.xlsx. **2019**,
- 271 Table_2.xlsx. **2019**,
- 270 DataSheet_1.docx. **2019**,
- 269 Image_1.tif. **2020**,
- 268 Image_10.TIF. **2020**,
- 267 Image_2.TIF. **2020**,

266 Image_3.TIF. **2020**,

265 Image_4.TIF. **2020**,

264 Image_5.TIF. **2020**,

263 Image_6.TIF. **2020**,

262 Image_7.TIF. **2020**,

261 Image_8.TIF. **2020**,

260 Image_9.TIF. **2020**,

259 Video_1.MP4. **2020**,

258 Video_2.MP4. **2020**,

257 DataSheet_1.pdf. **2019**,

256 Data_Sheet_1.PDF. **2020**,

255 Image_1.TIF. **2020**,

254 Table_1.xlsx. **2020**,

253 Presentation_1.PPTX. **2020**,

252 Table_4.xlsx. **2020**,

251 Data_Sheet_1.docx. **2020**,

250 Table_1.docx. **2020**,

249 Table_2.docx. **2020**,

248 Data_Sheet_1.pdf. **2019**,

247 Image_1.pdf. **2020**,

246 Image_2.pdf. **2020**,

245 Image_3.pdf. **2020**,

244 Image_4.pdf. **2020**,

243 Image_5.pdf. **2020**,

242 Image_6.pdf. **2020**,

241 Image_7.pdf. **2020**,

240 Table_1.pdf. **2020**,

239 Incorporating Omics Data in Genomic Prediction.. **2022**, 2467, 341-357

0

238 KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.. **2022**,

2

237 Insights into immune escape during tumor evolution and response to immunotherapy using a rat model of breast cancer.. **2022**,

1

236 Deep Mining from Omics Data.. **2022**, 2449, 349-386

235 Binary Bat Algorithm with Dynamic Bayesian Network for Feature Selection on Cancer Gene Expression Profiles. **2022**, 150-159

234 Precision diagnostics in cancer: Predict, prevent, and personalize. **2022**,

233 In Situ Analytical Tools to Resolve Stress Response Mechanisms of Foodborne Pathogens. **2022**, 575-607

232 Stitch Fix for Mapper and Topological Gains. **2022**, 265-294

231 Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.. **2022**, 6, e2100463

1

230	Dynamic Risk Prediction via a Joint Frailty-Copula Model and IPD Meta-Analysis: Building Web Applications. 2022 , 24, 589	2
229	Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review.. 2022 , 23,	4
228	A narrative review of five multigenetic assays in breast cancer.. 2022 , 11, 897-907	1
227	A boosting first-hitting-time model for survival analysis in high-dimensional settings.. 2022 ,	0
226	Sufficient principal component regression for pattern discovery in transcriptomic data.	
225	eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.. 2022 , 9, 877117	0
224	A Pairwise Imputation Strategy for Retaining Predictive Features When Combining Multiple Datasets.	
223	Bilim Teknolojileri Etmenlerinin Blok Tabanlı Kodlama Araştırma İçin İ Yeterlik Bana Bana Evrimisel Sinir Ağı ve Sınıflandırma	
222	GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis.. 2022 , 45, 329-342	
221	Association between tumor F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.. 2022 , 12, 7858	0
220	Gene expression signatures in early Breast Cancer: better together with clinicopathological features.. 2022 , 103708	0
219	A Novel Five-Gene Signature Related to Clinical Outcome and Immune Microenvironment in Breast Cancer. 2022 , 13,	0
218	Genomic Analysis of a Spontaneous Model of Breast Cancer Metastasis to Bone Reveals a Role for the Extracellular Matrix. 2005 , 3, 1-13	159
217	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. 2022 , 14, 2447	
216	ANLN and UBE2T are prognostic biomarkers associated with immune regulation in breast cancer: a bioinformatics analysis.. 2022 , 22, 193	2
215	Breast Cancer-Stromal Interactions: Adipose-derived stromal/stem cell Age and Cancer Subtype Mediated Remodeling.. 2022 ,	0
214	Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis.. 2022 ,	0
213	Development of Novel Cancer Biomarkers for Diagnosis and Prognosis. 2022 , 277-343	

212	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. 2022 , 42, 63-75	O
211	Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. 2022 , 12,	O
210	Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.	
209	The regulatory landscape of retinoblastoma: a pathway analysis perspective. 2022 , 9,	O
208	Machine learning enables accurate prediction of breast cancer five-year survival using somatic genomic variants.	
207	Advancing microfluidic diagnostic chips for clinical use.	1
206	The Ramp Atlas: facilitating tissue and cell-specific ramp sequence analyses through an intuitive web interface. 2022 , 4,	1
205	XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation. 2022 ,	1
204	A Novel Method for Feature Selection Based on Molecular Interactive Effect Network. 2022 , 114873	
203	Hypoxia Selectively Increases a SMAD3 Signaling Axis to Promote Cancer Cell Invasion. 2022 , 14, 2751	1
202	Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine. 2022 , 10, 1107	1
201	5bomiR-183-5p +2 elicits tumor suppressor activity in a negative feedback loop with E2F1. 2022 , 41,	
200	Translational Epidemiology in Cancer Research: The Less Travelled Path. 2022 , 349-366	
199	A Comprehensive Survey of Recent Hybrid Feature Selection Methods in Cancer Microarray Gene Expression Data. 2022 , 1-1	1
198	CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers.	O
197	Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. 2022 , 12,	O
196	NTN4 as a prognostic marker and a hallmark for immune infiltration in breast cancer. 2022 , 12,	1
195	NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. 2022 , 14, 2962	1

- 194 Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. **2022**,
- 193 MicroRNA-126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1. **2022**, 24,
- 192 L0-Regularized Learning for High-Dimensional Additive Hazards Regression. o
- 191 Targeting Breast Cancer-Derived Stem Cells by Dietary Phytochemicals: A Strategy for Cancer Prevention and Treatment. **2022**, 14, 2864 o
- 190 Breast cancer in the era of precision medicine. o
- 189 Circular RNA circ-ABCB10 Promotes Proliferation and Inhibits Apoptosis of Laryngeal Carcinoma by Inhibiting KLF6. **2022**, 2022, 1-8
- 188 Extended endocrine therapy in breast cancer: A basket of length-constraint feature selection metaheuristics to balance Type I against Type II errors. **2022**, 131, 104112
- 187 Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. **2022**, 32, 198-206 1
- 186 Perinucleolar Compartment Prevalence Has an Independent Prognostic Value for Breast Cancer. **2005**, 65, 246-253 19
- 185 Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. **2005**, 4, 151-170 17
- 184 Tissue-Based Biomarkers of Tumor-Vascular Interactions. **2022**, 17-30
- 183 A Comparative Study of Model Selection for High Dimensional Data. **2022**, 342-350
- 182 The evolution of gene expression profiling in breast cancer A narrative review. **2022**,
- 181 Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Phenotypes and Progress in Breast Cancer. **2022**, 401-424
- 180 Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. 9,
- 179 Role of germline variants in the metastasis of breast carcinomas. **2022**, 13, 843-862
- 178 Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence. o
- 177 The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. 1

176	Role of immunohistochemical markers in breast carcinoma and other breast pathologies: A review with a note on recent update. 2022 , 9, 23-29	
175	Degraded RNA from human anterior cruciate ligaments yields valid gene expression profiles.	
174	The risk of relapse in breast cancer patients is associated with MMP-9 gene polymorphism: a prospective study in a sample of the Iranian population. 1-12	
173	A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population. 12,	0
172	Design of Marker Panels for Prediction of Neoadjuvant Chemotherapy Response of Triple-Negative Breast Tumors Based on the Results of Genome-Wide DNA Methylation Screening. 2022 , 58, 835-843	
171	Deep survival forests for extremely high censored data.	
170	Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles. 2004 , 3, 161-168	6
169	Signatures of Environmental Exposures Using Peripheral Leukocyte Gene Expression: Tobacco Smoke. 2004 , 13, 445-453	24
168	Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival. 2005 , 11, 646-655	15
167	A Predictor Based on the Somatic Genomic Changes of the BRCA1/BRCA2 Breast Cancer Tumors Identifies the Non-BRCA1/BRCA2 Tumors with BRCA1 Promoter Hypermethylation. 2005 , 11, 1146-1153	19
166	Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis. 2005 , 65, 767-779	37
165	Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma. 2005 , 11, 1181-1189	22
164	Toward the Last Cohort. 2004 , 13, 895-897	6
163	Mammographic Density and Estrogen Receptor Status of Breast Cancer. 2004 , 13, 2090-2095	23
162	Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.	1
161	A Review of Artificial Intelligence and Robotics in Transformed Health Ecosystems. 9,	
160	Multi-Omics Binary Integration via Lasso Ensembles (MOBILE) for identification of context-specific networks and new regulatory mechanisms.	0
159	Prognosis of NonSmall Cell Lung Cancer Patients by Detecting Circulating Cancer Cells in the Peripheral Blood with Multiple Marker Genes. 2005 , 11, 173-179	27

- 158 Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets. **2022**, 17, e0252697
- 157 Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer. **2022**, 29, 5139-5149
- 156 Firmas gnicas en el cncer de mama. **2022**, 35, S67-S86
- 155 Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients. 13, 0
- 154 A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients. 13, 0
- 153 Bayesian nonnegative matrix factorization in an incremental manner for data representation.
- 152 A Review of the Nucleic Acid-Based Lateral Flow Assay for Detection of Breast Cancer from Circulating Biomarkers at a Point-of-Care in Low Income Countries. **2022**, 12, 1973 2
- 151 Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity. **2022**, 17, e0273164 0
- 150 Prediction of Breast Cancer Distant Metastasis by Artificial Intelligence Methods from an Epidemiological Perspective. **2022**, 23, 210-215 0
- 149 Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection. **2022**, 14, 4120
- 148 Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. **2022**, 13,
- 147 Phage antibodies against heat shock proteins as tools for in vitro cancer diagnosis. **2022**, 11, 100211
- 146 The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. **2022**, 178, 103781 1
- 145 Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?. **2022**, 110, 102454 1
- 144 Interlaboratory Comparability Study of Cancer Gene Expression Analysis Using Oligonucleotide Microarrays. **2005**, 11, 565-572 25
- 143 Deep View of HCC Gene Expression Signatures and Their Comparison with Other Cancers. **2022**, 14, 4322 0
- 142 Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. **2022**, 1
- 141 Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. **2022**, 175, 169-179 0

140	Deep survival forests with feature screening. 2023 , 79, 104195	0
139	Biomarkers, Prognosis, and Prediction Factors. 2023 , 49-70	0
138	Explainable machine learning of the breast cancer staging for designing smart biomarker sensors. 2022 , 3, 100202	3
137	Proposal of SVM Utility Kernel for Breast Cancer Survival Estimation. 2022 , 1-12	0
136	Using classification and K-means methods to predict breast cancer recurrence in gene expression data. 2022 , 12, 122	0
135	The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer. 2022 , 21, 153303382211174	0
134	Supporting shared decision making about surveillance after breast cancer with personalised recurrence risk calculations: the development of a patient decision aid using the IPDAS development process in combination with a mixed-methods design (Preprint).	0
133	Computational Studies in Breast Cancer. 2022 , 434-456	0
132	Development and testing of a polygenic risk score for breast cancer aggressiveness.	0
131	TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource. 2022 ,	1
130	Transcriptomic Harmonization as the Way for Suppressing Cross-Platform Bias and Batch Effect. 2022 , 10, 2318	0
129	Hybrid Feature Selection of Breast Cancer Gene Expression Microarray Data Based on Metaheuristic Methods: A Comprehensive Review. 2022 , 14, 1955	1
128	TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2. 2022 , 119,	1
127	Particle Swarm Optimization Artificial Intelligence technique for gene signature discovery in transcriptomic cohorts. 2022 ,	0
126	Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. 2022 , 2022, 1-12	0
125	MTRRE-Net: A deep learning model for detection of breast cancer from histopathological images. 2022 , 106155	1
124	Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study [a multicentre prospective observational cohort study. 2022 , 12, e061334	0
123	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. 12,	0

122	Collagen fiber features and COL1A1: are they associated with elastic parameters in breast lesions, and can COL1A1 predict axillary lymph node metastasis?. 2022 , 22,	0
121	Molecular Classification of Breast Cancer. 2022 ,	0
120	Effect of heat stress on DNA damage: a systematic literature review.	0
119	Big data in basic and translational cancer research.	3
118	Self-organizing map with granular competitive learning: Application to microarray clustering. 2022 , 16, 505-521	0
117	Spectrophotometric Detection of the BRCA1 Gene via Exponential Isothermal Amplification and Hybridization Chain Reaction of Surface-Bound Probes. 2022 , 38, 12050-12057	0
116	Gene reduction and machine learning algorithms for cancer classification based on microarray gene expression data: A comprehensive review. 2022 , 118946	1
115	Single Nucleotide Variants in KIF14 Gene May Have Prognostic Value in Breast Cancer.	0
114	Construction of novel lncRNA-miRNA-mRNA ceRNA networks associated with prognosis of hepatitis C virus related hepatocellular carcinoma. 2022 , 8, e10832	0
113	A graph based preordonnances theoretic supervised feature selection in high dimensional data. 2022 , 257, 109899	0
112	MiR-135a-5p suppresses breast cancer cell proliferation, migration, and invasion by regulating BAG3. 2022 , 77, 100115	0
111	Wildtype heterogeneity contributes to clonal variability in genome edited cells. 2022 , 12,	1
110	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. 12,	0
109	Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures. 13,	0
108	Bioinformatics and Experimental Analyses Reveal Immune-Related lncRNA-mRNA Pair AC011483.1-CCR7 as a Biomarker and Therapeutic Target for Ischemic Cardiomyopathy. 2022 , 23, 11994	0
107	Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients. 2022 , 14, 4844	0
106	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
105	Cancer Genomics and Evolution. 1-30	0

104	PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer. 13,	o
103	Prediction of Cancer Treatment using Advancements in Machine Learning. 2022 , 18,	o
102	Genomic Profiling and Liquid Biopsies for Breast Cancer. 2022 ,	o
101	Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report. 9,	o
100	A Robust Personalized Classification Method for Breast Cancer Metastasis Prediction. 2022 , 14, 5327	o
99	Systems Biology and Genomics. 1-11	o
98	The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment. 2022 , 23, 13029	o
97	A hybrid feature selection approach for Microarray datasets using graph theoretic-based method. 2022 , 615, 449-474	o
96	Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer. 28,	o
95	Label consistency-based deep semisupervised NMF for tumor recognition. 2023 , 117, 105511	o
94	Plectin as a putative novel biomarker for breast cancer: an in silico study. 2022 , 11,	o
93	Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree Via Metabolomics. 2022 , 14, 5589	o
92	KGA: integrating KPCA and GAN for microbial data augmentation.	o
91	Five-gene Signature for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Gastric and Urothelial Carcinomas. 2022 , 154233	o
90	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. 2022 , 14, 5668	1
89	Breast Cancer Pathology in the Era of Genomics. 2023 , 37, 33-50	o
88	Genomics and Disease Progression in IgA Nephritis. 2013 , 42, 674-680	o
87	Random Survival Forests Incorporated by the Nadaraya-Watson Regression. 2022 , 21, 851-880	o

86	Imputation Strategies for Clustering Mixed-Type Data with Missing Values.	0
85	The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity. 2022 , 12, 2985	0
84	Analysis of Proposed and Traditional Boosting Algorithm with Standalone Classification Methods for Classifying Gene Expression Microarray Data Using a Reject Option. 2022 , 36,	0
83	An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. 2022 , 11, 4121	0
82	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. 2022 ,	0
81	Artificial intelligence in breast cancer diagnostics. 2022 , 3, 100851	0
80	DNA methylation patterns define subtypes of differentiated follicular cell-derived thyroid neoplasms: an unsupervised machine learning approach.	0
79	Locally finite distance clustering with discriminative information. 2022 ,	0
78	Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer. 2022 , 45, 101885	0
77	A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer. 13,	0
76	Cancer Prognosis and Diagnosis Methods Based on Ensemble Learning.	0
75	Prognosis according to the timing of recurrence in breast cancer. 2023 , 104, 1	0
74	Polygenic risk score for prediction of radiotherapy efficacy and radiosensitivity in patients with non-metastatic breast cancer. 2023 ,	0
73	Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients. 2023 , 36, 83-96	0
72	A signature of immune-related genes correlating with clinical prognosis and immune microenvironment in sepsis. 2023 , 24,	0
71	Screening and identification of potential key biomarkers for glucocorticoid-induced osteonecrosis of the femoral head. 2023 , 18,	1
70	Memetic micro-genetic algorithms for cancer data classification. 2023 , 17, 200173	2
69	Self-supervised learning-based Multi-Scale feature Fusion Network for survival analysis from whole slide images. 2023 , 153, 106482	0

- 68 Feature selection combined with top-down and bottom-up strategies for survival analysis: A case of prognostic prediction in glioblastoma. **2023**, 153, 106486 ○
- 67 Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. **2023**, 242, 108337 ○
- 66 Comparing of feature selection algorithms. **2022**, ○
- 65 The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. **2023**, 11, 98 ○
- 64 A pairwise strategy for imputing predictive features when combining multiple datasets. **2023**, 39, ○
- 63 The investigation of levels of endothelial cell-specific molecule, progranuline, clusterin, and human epididymis protein 4 in the differential diagnosis of malignant pleural effusions. **2022**, 101, e32471 ○
- 62 Molecular Diagnostics. **2019**, 226-248 ○
- 61 A Two-Step Feature Selection Radiomic Approach to Predict Molecular Outcomes in Breast Cancer. **2023**, 23, 1552 ○
- 60 The genomic regulation of metastatic dormancy. ○
- 59 Matrix metalloproteinases as therapeutic targets in breast cancer. 12, ○
- 58 The emerging role of MCPH1/BRIT1 in carcinogenesis. 13, ○
- 57 Degraded RNA from Human Anterior Cruciate Ligaments Yields Valid Gene Expression Profiles. **2023**, 24, 1895 ○
- 56 Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 ○
- 55 Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification. ○
- 54 Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. ○
- 53 Automated Molecular Subtyping of Breast Carcinoma using Deep Learning Techniques. **2023**, 1-1 ○
- 52 A Comprehensive Investigation of Genomic Variants in Prostate Cancer Reveals 30 Putative Regulatory Variants. **2023**, 24, 2472 ○
- 51 Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. ○

- 50 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 49 Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients. **2023**, 136, 184-193 ○
- 48 Molecular Subtypes of Breast Cancer and CDk Dysregulation. **2023**, 133-148 ○
- 47 Opportunities and Challenges for the Development of MRCK Kinases Inhibitors as Potential Cancer Chemotherapeutics. **2023**, 12, 534 ○
- 46 Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers. **2023**, 231, 107401 ○
- 45 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 ○
- 44 Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. **2023**, 9, ○
- 43 Aiding Cancer's Sweet Tooth—Role of Hexokinases in Metabolic Reprogramming. **2023**, 13, 946 ○
- 42 Molecular principles of tissue invasion and metastasis. **2023**, 324, C971-C991 ○
- 41 Both fine-grained and coarse-grained spatial patterns of neural activity measured by functional MRI show preferential encoding of pain in the human brain. **2023**, 272, 120049 ○
- 40 The effect of attendance in the Dutch breast cancer screening program on breast tumor characteristics among migrant women. **2023**, 69, 290-298 ○
- 39 Meta-analysis of engineered nanoparticles dynamic aggregation in freshwater-like systems using machine learning techniques. **2023**, 337, 117739 ○
- 38 Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. **2023**, 23, 41-51 ○
- 37 Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility. **2023**, 128, 1208-1222 ○
- 36 Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs. **2023**, 4, 100932 1
- 35 Molecular profiling in contemporary breast cancer management. ○
- 34 Evaluation and comparison of different breast cancer prognosis scores based on gene expression data. **2023**, 25, ○
- 33 A New Evolutionary Ensemble Learning of Multimodal Feature Selection from Microarray Data. ○

- 32 Hybrid Filter and Genetic Algorithm-Based Feature Selection for Improving Cancer Classification in High-Dimensional Microarray Data. **2023**, 11, 562 1
- 31 Premenopausal women with breast cancer in the early postpartum period show molecular profiles of invasion and are associated with poor prognosis. o
- 30 Lessons from other fields of medicine, Part 1: Breast cancer. **2023**, 101-118 o
- 29 Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients. o
- 28 Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor-Positive Breast Cancer. **2023**, 6, e230179 o
- 27 Exploration of prognostic genes and risk signature in breast cancer patients based on RNA binding proteins associated with ferroptosis. 14, o
- 26 Cancer Diagnostics. **2023**, 459-481 o
- 25 Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. **2023**, 14, o
- 24 Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions. **2023**, 25, 491-500 o
- 23 Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence. **2023**, 15, 48-57 o
- 22 Sensitivity Analysis for Survival Prognostic Prediction with Gene Selection: A Copula Method for Dependent Censoring. **2023**, 11, 797 o
- 21 Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. 14, o
- 20 Improving the robustness and stability of a machine learning model for breast cancer prognosis through the use of multi-modal classifiers. **2023**, 13, o
- 19 Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. **2023**, 12, 926 o
- 18 Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. o
- 17 Disease progression based feature screening for ultrahigh-dimensional survival-associated biomarkers. o
- 16 Special Studies. **2013**, 279-304 o
- 15 Loss of TTC17 promotes breast cancer metastasis through RAP1/CDC42 signaling and sensitizes it to rapamycin and paclitaxel. **2023**, 13, o

- 14 Multimodal feature selection from microarray data based on Dempster-Shafer evidence fusion. ○
- 13 Molecular breast cancer subtype identification using photoacoustic spectral analysis and machine learning at the biomacromolecular level. **2023**, 30, 100483 ○
- 12 The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial-Mesenchymal Transition. **2023**, 24, 6422 ○
- 11 Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER. **2023**, ○
- 10 RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. **2023**, 23, ○
- 9 Majority voting based on different feature ranking techniques from gene expression. **2023**, 1-15 ○
- 8 A New hybrid Feature selection-Classification model to Improve Cancer Sample Classification Accuracy in Microarray Gene Expression Data. **2023**, ○
- 7 Applying a GAN-based classifier to improve transcriptome-based prognostication in breast cancer. **2023**, 19, e1011035 ○
- 6 Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy. **2023**, 3, ○
- 5 A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patients. ○
- 4 Bioengineering and Bioinformatic Approaches to Study Extracellular Matrix Remodeling and Cancer-Macrophage Crosstalk in the Breast Tumor Microenvironment. **2023**, 201-229 ○
- 3 Development and validation of a nomogram for predicting axillary lymph node metastasis in breast cancer. **2023**, ○
- 2 The Role of TGF- β in Radiation Response. **2023**, 24, 7614 ○
- 1 Single cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug resistant states. ○